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Abstract 
Glioblastoma is a World Health Organisation (WHO) grade IV tumour which 
remains the most aggressive and common malignant brain tumour in adults.[1] 
The average 2-year survival of glioblastoma patients is sadly only around 25%.[2] 
Glioblastoma tumours arise in the glial cells of the brain; these tumours have 
protruding fibres that infiltrate into other areas of the brain creating a support 
network for the tumour.[3][4] Glioblastoma is associated with poor prognosis and 
survival rates, which have not increased significantly enough in recent years, 
especially when compared to other cancers, such as breast and colon cancer.[5][6] 
Although the available interventions are effective and offer improved prognosis, 
they cannot eradicate all glioblastoma tumour cells, giving reasons for the 
extremely high re-occurrence rates. Therefore, a more effective pharmaceutical 
agent is necessary for the treatment of glioblastoma.  
In the search for new chemotherapeutic agents, the dietary phytochemicals found 
in cruciferous vegetables have gained considerable attention. In particular, the  
dimeric product of indole-3-carbinol (I3C); 3,3’-diindolylmethane (DIM, Figure 1).  
 
 
 
Figure 1- The structure of the lead compound, 3,3’-diindolylmethane (8). 
The anti-cancer effects of DIM and its c-substituted derivatives, known as c-DIMs, 
have been established against a number of different cancer cell types.[7][8][9][10]  c-
DIMs are characterised by substitution at the methylene carbon bridge of DIM, 
and their effects towards glioblastoma are currently unknown. Therefore, using 
DIM as a basic scaffold,  a series of symmetrical functionalised DIM derivatives 
have been synthesised.  
DIM and the synthesised compounds underwent in vitro screening studies, using 
the MTS assay, to identify their anti-proliferative effects towards the human 
glioblastoma cell line U-87 MG. Compounds 19, 17 and 65 (Figure 2) exhibited 
the highest activity, with IC50 values of 31.6 μM, 38 μM and 33.1 μM respectively. 
 
DIM, 8
3 
 
19
17
65
 
Figure 2 – The structures of compounds 19, 17 and 65, the compounds that 
exhibited the best anti-glioblastoma activity. 
To conclude, this project identifies c-DIM analogues, that display respectable 
anti-cancer activity towards glioblastoma cells. The active compounds 
synthesised in this project, provide a good basis for the future synthesis of a wider 
library of compounds, and further investigation into the use of DIM derivatives for 
the treatment of glioblastoma. 
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Chapter 1 – Introduction 
1.1 Cancer  
Cancer is a worldwide burden on the population, affecting people of any age, 
gender or ethnicity. According to GLOBOCAN 2018, there were approximately 
18.1 million new cases of cancer and 9.6 million deaths last year. It is estimated 
that 1 in 2 people will develop cancer at some point of their lives, and although 
cancer survival rates are higher than ever, this is still a stark statistic to 
comprehend.[11] 
Figure 3 – Pie charts showing new cases of cancer in 2018 (left), and the 
number of cancer deaths in 2018 (right).[11] 
Over a century ago, German cytologist Theodor Boveri proposed that 
chromosomal defects could cause a cell to proliferate abnormally, essentially 
suggesting that cancer is a “disease of the genome”.[12] This took 70 years to 
prove, by showing the presence of mutated cancer-causing genes. Some years 
later, the main types of cancer causing and cancer suppressing genes 
(oncogenes and tumour suppressor genes) had been identified, alongside the 
genomic alterations that give rise to these cancer-causing genes (e.g. nucleotide 
substitutions, DNA rearrangements and chromosomal copy number 
alterations).[13] These findings hinted at the complexity of the genetic mutations 
that cause cancer, as these genes vary across tumour types and the fact that 
multiple genes contribute to oncogenesis.  
Over the past few decades, extensive research has been carried out to identify 
risks associated with cancer, factors that may cause or encourage the genetic 
mutations that cancer arises from. For several cancers, there are established 
environmental factors in cancer causation, for example, smoking and lung 
22 
 
cancer, human papillomavirus (HPV) and cervical cancer, UV radiation exposure 
and skin cancer and Helicobacter pylori (H.pylori) and gastric cancer.[14] 
Hereditary factors also play a role, confirmed by twin studies and the identification 
of genetic predispositions for particular cancers, for example mutations of the 
BRCA1 or BRCA 2 genes can increase the risk of breast and ovarian cancer. 
However, only around 5-10% of cancers are caused by inherited genes.[15] 
The increase in incidences of cancer can generally be attributed to the increase 
in life expectancy and the ever-expanding population. The ageing process is 
considered the most significant factor in the development of cancer, as cancer is 
a result of random mutations during DNA replication which occurs more as a 
person ages. Figure 4 shows how the risk of cancer increases with the number 
of cell divisions relative to the tissue type the cancer arises from. Surprisingly, 
only one third of cancer risk is currently known to be caused by environmental or 
hereditary factors and sadly, the remaining two thirds are down to “bad 
luck”.[15][16][17] 
Figure 4 – Lifetime risk of cancer for specific cancer types vs number of total 
stem cell divisions.[17] 
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1.2 – Brain tumours 
1.2.1 – Brain tumours 
Brain tumours, better described as intracranial neoplasms, are tumours that arise 
from cells within the brain. They can be either malignant (cancerous) or benign 
(non-cancerous) tumours, they can then be divided into primary tumours or 
secondary tumours. Primary brain tumours arise from tissues within the brain, 
they are significantly more prevalent in children under 15 years of age and the 
elderly.[18] The most frequent primary brain tumours are: gliomas (50.4%), 
meningiomas (20.8%), pituitary adenomas (15%) and nerve sheath tumours 
(8%).[19] Secondary brain tumours are metastatic, whereby cancer from 
elsewhere in the body has spread to the brain. This most commonly occurs from 
bladder cancer, breast cancer, melanoma, kidney cancer and leukaemia.[20] The 
World Health Organisation (WHO) provides a grading of brain tumours (Table 1) 
that is recognised globally, this allows for worldwide research and 
epidemiological studies. Brain tumours are graded depending on their 
malignancy, suspected cell type of origin and rate of cell proliferation. For 
example, tumours that originate from ependymocytes are termed ependymomas, 
whereas tumours derived from astrocytes are known as astrocytomas. The 
malignancy is graded from I-IV, whereby grade I and II tumours have low mitotic 
activity, are unlikely to spread and are associated with good prognosis. However, 
grade III and IV tumours are very malignant, have a high rate of proliferation, 
infiltrate other areas of the brain and are associated with poor prognosis.[1][21]  
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Table 1 – Grading of select brain tumours according to the WHO 2016.[1] 
GLOBOCAN 2018 states, 296,581 people worldwide were diagnosed with a brain 
or central nervous system (CNS) tumour, and in the same year there were 
241,037 deaths as a result of brain and CNS tumours.[22] Although the diagnostic 
figures seem low in comparison to other cancers such as breast and lung cancer, 
the survival rates are much poorer. Only 14% of people diagnosed with a brain 
tumour will survive for more than 10 years and only 40% of patients with a 
malignant brain tumour will live over one year.[23] Brain tumours propose a 
significant challenge in terms of diagnosis, treatment and survival. Thus, a much 
more effective regime is required. 
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1.2.2 – Causes of brain tumours 
The etiology of brain tumours has been widely researched, yet cause factors have 
not been established. Epidemiological studies have been burdened as a result of 
the rarity and complexity of these tumours, alongside the fact that brain tumours 
are thought to differ relative to the cell type the tumour originated from.[24] A 
number of hereditary disorders such as tuberous sclerosis, von Hippel-Lindau 
disease and type 1 and 2 neurofibromatosis, have been associated with a genetic 
predisposition to the development of brain tumours.[25] Neurofibromatosis type 1, 
also known as von Recklinghausen disease is the most frequent and is 
associated with gliomas of hamartomas and the optic nerves. On the other hand, 
neurofibromatosis type 2 is linked to meningiomas, ependymomas and 
schwannomas.[26] 
Certain occupations have been connected to a higher risk of developing brain 
tumours, for example, farmers as pesticide exposure is a suspected risk factor. 
A case-control study investigating the potential carcinogenetic effects of pesticide 
for agricultural purposes found a notable association between pesticide use and 
the development of gliomas later on in life. However, it is worth noting, that recall 
bias was an issue within this study, suggesting further research is required.[27] A 
study by Provost et al investigated a link between brain tumours and pesticide 
exposure in southwestern France, which states that only a significantly high level 
of exposure could be associated with the development of brain tumours, gliomas 
especially.[28] Occupations involving exposure to certain chemicals such as 
rubber, vinyl chloride, mercury and formaldehyde have also raised speculation in 
their role in the development of brain tumours.[29] 
There are other suspected risk factors linked to the causation of brain tumours, 
e.g. radiofrequency waves (use of mobile phones), previous head trauma, 
smoking and viral infections.[29] However attempts to prove the relationships 
between these risk factors and brain tumours, sadly remains inconsistent.[29]  
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1.2.3 – Signs and symptoms 
Symptoms of brain tumours can vary dependent on its location within the brain, 
the type of tumour and tumour size. Symptoms are usually the result of the 
tumour pressing on the brain – intercranial pressure, blocking the movement of 
fluid flowing through the brain causing a build-up of fluid or by pressing on nerves 
in the brain.[30] The most common symptoms include headaches, problems with 
memory and concentration, nausea and vomiting, poor vision, numbness of the 
limbs, seizures and loss of balance.[31] As these symptoms can be caused by 
numerous other health conditions and a patient may only have a few of these 
symptoms, it can make early diagnosis of brain tumours difficult. 
Psychological distress is extremely prevalent amongst brain tumour patients, 
depression in patients with highly malignant tumours was reported as high as 
93%.[32] Other issues such as extreme sleep disturbances, anxiety and fatigue 
are also common complaints amongst patients with high grade tumours.[32] 
 
1.2.4 - Diagnosis 
The first stage of diagnosis is usually a neurological exam, consisting of checking 
reflexes, hearing, co-ordination, balance, and memory. Subsequently, imaging 
tests are carried out, the preferred modalities are magnetic resonance imaging 
(MRI) and computerised tomography (CT). These tests have an excellent ability 
to locate brain tumours, identify the size of the tumour, and evaluate 
complications such as oedema, hydrocephalus and brain haemorrhages.[33] 
Additionally, doctors use these images to predict the tumour type. Positron 
Emission Tomography (PET) scans can also be used, with the assistance of 
radioactive tracer fluorodeoxyglucose (FDG) to represent the metabolic uptake 
of glucose.[34][35] These scan images are usually combined to create treatment 
plans. Figure 5 illustrates a CT, MRI, PET/CT scan of a 62 year old male 
glioblastoma patient, the scan images were combined to calculate a radiotherapy 
plan. Similarly, Figure 6 also shows a CT, MRI, PET/CT scan and their 
combination in order to create a radiotherapy plan, however, for a 50 year old 
male with nodular atypical meningioma.[36]  
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Figure 5 – CT and MRI scan combined with a PET/CT scan of a 62 year old 
male with glioblastoma to produce a radiotherapy plan.[36] 
 
Figure 6 - CT and MRI scan combined with a PET/CT scan of a 50 year old 
male with nodular atypical meningioma to create a radiotherapy plan.[36] 
Despite the fact imaging techniques are extremely useful, MRI, FDG-PET and 
CT scans are unable to provide accurate insights into specific tumour type, 
therefore histological tests via biopsies are also required to make an accurate 
diagnosis. 
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1.3 – Glioblastoma 
1.3.1 – Classification of glioblastoma 
Glioblastoma (GB) is a grade IV astrocytoma, it can also be called a malignant 
astrocytic glioma.[37] It is the most aggressive and lethal primary malignant brain 
tumour in adults, it is slightly more common in males and its incidence increases 
with age. GB has extremely poor prognosis, median survival for patients is around 
6–9 months from time of diagnosis and even in the most positive circumstances 
long term survival is rare, with 25% of patients surviving two years.[1][2]  
Glioblastomas are conventionally split into primary and secondary tumours; the 
former, known as IDH-wildtype is a GB arising de novo, and the latter IDH-mutant 
are GB tumours derived from lower grade anaplastic astrocytomas or diffuse 
astrocytomas. GB tumours that are indistinguishable between primary and 
secondary are referred to as glioblastoma not otherwise specified (NOS).[1][38] 
Primary and secondary GB tumours involve significant genetic differences, 
suggesting they evolve via different genetic pathways. Genetic characteristics 
typical of primary glioblastomas are, predominantly, loss of heterozygosity (LOH) 
on chromosome 10p (approximately 70% of cases), EGFR amplification, and 
mutation of protein PTEN. In contrast, secondary glioblastomas show TP53 
mutations, the most common and earliest alteration to detect as it is already 
present in approximately 60% of low grade astrocytomas. Additionally, LOH is 
observed of chromosomes 13p, 17p, 19p and increased telomerase 
activity.[39][40][41] 
Primary GB is much more common, accounting for 90% of all cases and tend to 
grow quickly in elderly patients. Whereas, secondary tumours are less frequent, 
occur in younger patients, prefer developing within the frontal lobes of the brain 
and are associated with a more positive prognosis.[1] Table 2 summaries the key 
characteristics associated with primary and secondary glioblastoma tumours, 
according to the WHO 2016.  
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Table 2 – Key characteristics of IDH-wildtype glioblastoma and IDH-mutant 
glioblastoma.[1] 
 
1.3.2 – Current treatments 
After diagnosis, surgical resection is the initial form of treatment, as studies 
demonstrate a positive correlation between extent of removal (EOR) and 
survival.[42] Neurosurgeons aim to achieve a balance between maximum removal 
of tumour mass with minimal neurological impairment. Therefore, prior to surgery 
the EOR is determined in order to avoid damage to eloquent areas of the brain. 
If resection is expected to cause neurological impairment, then a stereotactic 
biopsy is performed. Although surgery is essential and extends survival 
significantly more in comparison with patients that only undergo biopsy 
(approximately 7 months vs 3.5 months, respectively), recurrence is 100%.[43] 
Glioblastoma tumours have poor marginalisation, due to their extremely 
infiltrative nature. They tend to migrate along the white matter tracts of the brain 
and troublingly, they have been found to migrate up to 5 cm from their ‘visible’ 
margins.[44] 
Fluorescence guided surgery (FGS) is a surgical technique that may be used to 
improve the EOR, involving the use of fluorescent dyes with high tumour 
specificity, FGS can improve the visualisation of the tumours beyond their visible 
borders. The use of 5-aminolevulinic acid (5-ALA) is currently the only agent 
approved for high grade glioma (HGG) surgery in Japan, Canada and Europe.[45] 
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5-ALA is a precursor of haemoglobin and is converted into fluorescent porphyrins 
(PpIX) during the heme synthesis in mammalian cells (Scheme 1).[46]  
 
 
Scheme 1 – Reaction scheme showing the formation of PpIX from 5-ALA 
during the heme synthesis. M, methyl side chain. V, vinyl side chain.[46] 
PpIX molecules have a preference for malignant glioma cells due to the variation 
in haemoglobin synthesis in tumour cells and normal cells, therefore the 
fluorophores accumulate within the tumour.[47] PpIX emits light within the red 
region of the spectrum, producing pink fluorescence under blue-violet light 
conditions, allowing for differentiation between cancerous and normal tissues, 
which might otherwise be in  distinguishable.[48] In a 2006 a randomised controlled 
multi-institution phase III trial, investigating the effects of fluorescence-guided 
surgery with 5-ALA versus white light surgery was carried out. Resection of 65% 
was achieved for 5-ALA patients, in comparison to 36% for white light patients. 
Moreover, 6-month progression-free survival was found to be 41% for 5-ALA 
patients and 21.1% for white light patients.[49][50]  
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Figure 7 – Photo taken during glioblastoma resection using 5-ALA. Under white 
light (left) it seems tumour has been entirely removed. The yellow line indicates 
tumour border according to MRI. Under blue light (right), residual tumour is 
seen.[50] 
Despite demonstrating promising advancements in the resection of high grade 
gliomas (HGG’s), 5-ALA does have disadvantages. PpIX can give false positive 
results via leaking into nearby fluid in the brain, giving the appearance more 
tumour is present.[51] Also, side effects such as photosensitivity, nausea, 
hypotension and raised liver enzyme levels were reported up to 48 hours after 
the drug was administered.[51] 
Although surgery is the most efficient intervention in extending the overall survival 
(OS) and relieving patients of painful symptoms, such as headaches and 
seizures, residual tumour cells always remain after surgery and recurrence is 
inevitable. Therefore, follow up treatments are essential.[51] 
Radiotherapy (RT) has played a key role in GB treatment since the 1980’s, when 
it was discovered that post-surgery therapeutics aid overall survival.[52][53] RT is 
based on ionising radiation dealing damage to the DNA of tumour cells, disrupting 
the mechanisms associated with cell division and thus preventing tumour growth. 
Radiotherapy treatment is usually started 4 to 6 weeks after surgery, over a 6 to 
7 week period, the standard dose is a total of 60 gray units (Gy) in daily doses of 
2Gy, 5 days a week.[54] 
In the past, GB patients were given whole brain radiotherapy (WBRT), however, 
it was associated with cognitive issues and high doses were required.[55][56] 
Currently, sophisticated planning is carried out using CT scans before RT is 
administered. There are three essential volumes to consider; the first is the known 
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gross tumour volume (GTV), which is usually the visible tumour mass. The 
second is the clinical target volume (CTV), which encases the GTV and accounts 
for tumour spread that is not visible. Finally, the planning target volume (PTV) 
which takes into account both internal and external uncertainties.[57][58]  
 
 
 
 
 
 
 
 
Figure 8 - CT scan of a grade IV glioblastoma patient showing planning 
volumes for RT treatment.[58] 
In addition to maximum surgical resection and RT, the use of pharmaceutical 
agents are also used to further destroy and inhibit the growth of glioblastoma 
cells. After surgery, chemotherapy treatment is started, either at the same time 
or shortly after RT.[59] Oncologists devise carefully tailored chemotherapy plans 
for glioblastoma patients, due to the extremely heterogeneous nature of 
glioblastoma tumours.[60] Carmustine is a commonly used medication for the 
treatment of high-grade gliomas, Bevacizumab can be used as a secondary 
treatment for recurrent glioblastoma, Lomustine is a drug sometimes used 
alongside Bevacizumab to improve the effectiveness of Bevacizumab.[61] 
Chemotherapy medications can be administered orally, intravenously and in 
special circumstances injected into the intrathecal space of the spine.[61] 
Carmustine can also be implanted into the tumour cavity in a biodegradable 
wafer, known as gliadel wafers.[61][62] However, the use of these wafers is 
controversial, the implantation of wafers offer a slight improvement of less than 
six weeks. Moreover, side effects reported include myelosuppression, intracranial 
infections and worsening of neurological deficits.[62]  
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Currently, the initial chemotherapeutic agent of choice for the treatment of newly 
diagnosed glioblastoma patients is temozolomide.[63] Initially, radiotherapy was 
trialled as a monotherapy after surgery in the treatment of glioblastoma. However, 
in 2005 a phase III randomised controlled trial concluded that radiation therapy 
combined with temozolomide increased the OS of glioblastoma patients by 2.5 
months (12.1 versus 14.6 months OS). Since then, this has become the gold 
standard of care for healthy adults with recently diagnosed GB.[63] Typically, the 
recommended dose of TMZ for newly diagnosed GB patients receiving 
concomitant radiation plus chemotherapy, is 75mg per day for 5 days over a 6-
week period. Side effects such as nausea, tiredness and sleep problems were 
reported but otherwise TMZ is well tolerated.[64] 
TMZ (1) is an oral alkylating drug belonging to the imidazotetrazine family, it is a 
small molecule with a molecular weight of 194 g/mol, thus is easily absorbed into 
the bloodstream, its bioavailability is approximately 100%. Its lipophilic properties 
also allow it to penetrate the blood brain barrier (BBB).[65] TMZ acts as a prodrug, 
stable in the acidic environment of the stomach, however, labile once absorbed 
into the bloodstream (pH 7). TMZ undergoes spontaneous hydrolysis to yield 3-
methyl-(triazene-1-yl)imidazole-4-carboxamide (MTIC, 2). MTIC then reacts with 
water to liberate 5-aminoimidazole-4-carbozamine (AIC, 3) and the active 
species - the methyldiazonium cation (4, see Scheme 2).[66][67]   
Scheme 2 – Mechanism showing the metabolism of TMZ (1) in aqueous 
media.[67] 
34 
 
The methyldiazonium (4) ion formed via the metabolism of TMZ (1), methylates 
guanine and adenine residues within DNA, most frequently occurring at the N7-
position of guanine, then the N3-position of adenine, followed by the O6-position 
of guanine (O6-MeG). While the (O6-MeG) lesion is the least common 
methylation, it is responsible for the cytotoxic effects of TMZ towards GB cells.[67] 
In normal cells the enzyme methylguanine methyltransferase (MGMT) removes 
the methyl group and restores guanine. However, in MGMT deficient cells, during 
DNA replication, O6-MeG pairs with thymine instead of cytosine, in turn activating 
DNA mismatch repair (MMR), which identifies the mismatch and destroys the 
daughter strand of DNA. As the O6-MeG still exists in the template strand, this 
causes repetitive DNA strand breaks and ultimately cell apoptosis via G2/M cell 
cycle arrest.[68][69]  
Glioblastoma tumours that initially respond well to chemotherapy, can eventually 
develop a resistance to the drug – this is known as acquired resistance. Explained 
by Darwinian evolution, acquired resistance to TMZ is the outcome of drug-
induced changes to genes in neoplastic cells. By inducing and selecting genes 
that have a survival advantage.[70] Patients experiencing an ineffectiveness of 
TMZ can be attributed to having increased levels of MGMT and insufficient MMR. 
Zhang et al reported that increased up-regulation of MGMT in U373 glioblastoma 
cells that were treated with TMZ, showed a 4-fold resistance to TMZ.[71] In 
addition, cancer stem cells and the presence of efflux pumps that actively pump 
drugs out of the tumour cells, such as P-glycoprotein, have been associated with 
resistance to treatment.[72]  
1.3.3 – Conclusion  
To conclude, glioblastoma is a deadly brain tumour and despite the 
advancements in imaging, radiotherapy, surgery and chemical agents, prognosis 
is dismal. A more effective regime, in the diagnosis and treatment of glioblastoma 
is essential, preferably earlier diagnosis and the development of more effective 
pharmaceutical agents with high tumour specificity, the ability to pass the BBB 
and minimal adverse side effects.   
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1.4 - The anti-cancer effect of 3,3’-diindolylmethane (DIM) and its derivatives 
1.4.1 – Introduction 
Dietary intake has always contributed to defining a person’s health, and an 
increased consumption of fruit and vegetables is recommended in order to avoid 
the development of chronic diseases, including cancer. According to The World 
Cancer Research Fund, approximately 3 to 4 million cases of cancer worldwide 
could be avoided via making healthy lifestyle choices, it is proposed that 
micronutrients such as antioxidants and phytochemicals may possibly have anti-
cancer properties.[73] This has led to research aiming to establish this link and to 
identify the components responsible for the chemopreventive properties.[74] A 
meta-analysis of 14 case-controlled studies concluded that the risk of developing 
breast cancer was decreased by 25% by an increased vegetable intake.[75] 
Epidemiological studies have also been carried out to investigate the effects of 
higher vegetable consumption amongst populations and occurrences of cancer. 
A study involving Dutch men and women found that those with the highest 
vegetable intake were at lower risk of developing colon cancer than those with 
lesser intakes.[76] In a review analysing results from 206 epidemiological studies 
and 22 animal studies, there was evidence that a higher fruit and vegetable 
consumption provides a protective effect for several cancers, including pancreas, 
endometrium, lung, pharynx and colon.[77] The type of fruit and vegetables that 
most frequently demonstrated the protective effect were cruciferous vegetables. 
Cruciferous vegetables are vegetables of the Brassicaceae family, including 
broccoli, cabbage, cauliflower, watercress and collard greens. Considerable 
research has found possible associations between cruciferous vegetable intake 
and reduced risks of cancer.[78][79][80] This Includes a meta-analysis carried out in 
the US, that found women who consumed more than 5 servings of cruciferous 
vegetables per week had a reduced risk of lung cancer.[81] This association 
between reduced risk of cancer and increased cruciferous vegetable intake, has 
led to the study of cruciferous vegetables’ bioactive constituents being studied for 
use in the prevention and treatment of cancer.[82] 
Cruciferous vegetables are a rich source of glucosinolates – substituted β-
thioglucoside N-hydrosulfates - glucosinolates are derived from amino acids, 
which upon hydrolysis form isothiocyanates, with the exception of those derived 
from tryptophan which yield indoles. The composition varies significantly with the 
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type of plant. For example, watercress is rich in gluconasturtiin, whereas broccoli 
has a high glucoraphanin content. The levels of glucosinolates can also vary 
dependent on environmental factors such as soil pH, iron presence and 
temperature.[83][84] Glucosinolates are hydrolysed via the enzyme myrosinase to 
produce a variety of isothiocyanates and indoles. A glucosinate of interest, 
namely glucobrassicin (5), upon hydrolysis produces indole-3-methyl 
isothiocyanate (6) via a C-N (Lossen) rearrangement, this rapidly yields the 
corresponding alcohol - indole-3-carbinol (I3C, 7) and a thiocyanate ion (see 
Scheme 3).[85] In the acidic environment of the gut, indole-3-carbinol is extremely 
unstable and undergoes reactions to produce a spectrum of products, at least 15 
different oligomeric products. However, primarily formed is the dimeric product of 
I3C – 3,3’-diindolylmethane (DIM, 8, Scheme 3) - thought to be the most 
biologically active and most stable metabolite of I3C, and it is DIM that is believed 
to have the anti-cancer effect.[8][86] Attempts to investigate the chemopreventive 
and anti-carcinogenic properties of I3C have proved difficult due to its instability 
in aqueous media. For example, a phase I trial administered oral doses of I3C 
(400-1200 mg) to women, subsequently, serial plasma samples were analysed 
via HPLC. No I3C was detected in plasma and the only derivative product of I3C 
detectable in plasma was DIM.[87]  
 
Scheme 3 – The metabolism of glucobrassicin into I3C (7) and DIM (8).[85] 
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1.4.2 – 3,3’-Diindolylmethane 
1.4.2.1 – The structure of  3,3’-diindolylmethane  
Indole is a planar bicyclic molecule consisting of a benzene ring fused to a 
nitrogen-containing pyrrole ring. Thought to be one of the most privileged 
heterocycles known, this particular structure is found in many natural and 
synthetic products. For example, the anti-tumour agent mitomycin C (Figure 9, 9) 
which undergoes bio-reductive activation, causing the formation of cross-links 
with DNA to prevent replication of cancer cells. Also, the naturally occurring 
amino acid tryptophan (Figure 9, 10).[8][88]  
 
 
 
 
 
 
 
Figure 9 - Chemical structures of anti-cancer agent mitomycin C and the amino 
acid tryptophan. 
Due to the biological activity of the indole nucleus, its derivatives have therefore 
been widely implemented in drug design. For example, vincristine (11) and 
vinblastine (12, see Figure 10) are indole containing chemotherapeutic agents 
that have been used when treating Hodgkin’s lymphoma, leukaemia and breast 
cancer.[89]  
 
mitomycin C, 9 
tryptophan, 10 
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Figure 10 - Chemical structures of indole containing chemotherapy drugs 
vincristine and vinblastine.[89] 
The 3,3’-diindolylmethane (8) skeleton is a symmetrical structure comprised of 
two indole rings bound by a methylene bridge at position-3 of the indole rings 
(Figure 11).  
8
 
Figure 11 – The chemical structure of 3,3’-diindolylmethane (8). 
 
1.4.2.2 – The anti-cancer effect of 3,3’-diindolylmethane 
Studies have established the anti-cancer effects of DIM against a number of 
cancer cell lines. A study by Nicastro et al, investigated the effects of DIM at 
different concentrations (0-25 μM), on breast cancer growth.[90] It was established 
that DIM inhibited tumour growth, showing a positive correlation between DIM 
concentration and tumour growth inhibition. From 30 minutes to 24 hours of 
administration DIM inhibited cell proliferation by 54% and cell migration by 
66%.[90] Importantly, DIM did not have an effect on non-tumorigenic cell lines, 
demonstrating its ability to distinguish between healthy and cancerous cells; 
enhancing its applicability to a clinical setting. A similar investigation was carried 
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out by Vivar et al, in which they tested the effects of DIM against human prostate 
cancer cells.[7] It was concluded that DIM inhibited the growth of prostate cancer 
cells, and specifically, it was identified that DIM prevented the progression of 
cancer cells into the S phase via inducing a G1 phase-specific cell cycle arrest.[7] 
Additionally, research by Li et al shows that DIM inhibits gastric cancer cells via 
G1 phase cell cycle arrest by decreasing levels of cyclin dependant kinases. DIM 
also increased cellular pro-apoptotic protein and p53 levels.[91]  
There is also evidence DIM exhibits anti-carcinogenic effects against other types 
of cancer such as; oesophageal, colorectal, liver and pancreatic.[92][93][94][95] The 
mechanisms by which DIM inhibits the growth of cancer cells varies amongst 
cancer types but are well studied. The most commonly noted ones include; 
induction of endoplasmic reticulum (ER) stress, Go and G1 cell cycle arrest, 
apoptosis and activation of the aryl hydrocarbon receptor (AhR).[96][97] In the USA, 
DIM is currently used in the adjuvant therapy of recurrent respiratory 
papillomatosis, a rare disease caused by HPV, whereby tumours form in the 
upper respiratory tract.[98][99]  
In addition to the basic DIM structure, in vitro screening studies have established 
that 2,2’-substituted DIM compounds also demonstrate an anti-proliferative effect 
towards breast cancer by inhibiting the epidermal growth factor (EGFR) 
pathway.[100] Ghosh et al, identified that 2,2’-diphenyl DIM (13, Figure 12), 
induced a 50% decrease in cell proliferation (IC50 value of 50 μM) at 
concentrations below 20 μM in breast cancer cell lines. The cytotoxicity of 2,2’-
phenyl DIM (13) towards non-cancerous cells was also investigated, in which it 
was concluded that 13 was non-cytotoxic to healthy cells up to concentrations of 
50 μM.[100]  
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2,2'-diphenyl DIM, 13 2,2'-dimethyl DIM, 14
N,N'-dimethyl DIM, 15 N,N',2,2'-tetramethyl DIM, 16 
Figure 12 – Chemical structures of N,N’- and 2,2’-methyl-substituted DIM 
derivatives (13-16) tested for anti-proliferative effects against breast cancer 
cells.[100][101] 
Similar to the research carried out by Ghosh et al, Safe et al investigated the 
effects of methyl-substituted DIM analogues against breast cancer cells. They 
found that 2,2’- (14), N,N’-dimethyl DIM (15) and N,N’,2,2’-tetramethyl DIM (16) 
(Figure 12) all inhibited estrogen-induced T47D breast cancer cell growth by 
acting acts as selective FDG modulators.[101]   
1.4.3 – c-substituted 3,3’-diindolylmethane derivatives 
The previously discussed findings provide evidence of the anti-cancer effects of 
DIM. Using DIM as a template, additional research into the anti-tumorigenic 
properties of c-functionalised DIM derivatives (c-DIMs) show promising prospects 
for DIM derivatives as anti-cancer agents. c-DIMs are characterised by 
substitution at the carbon of the methylene bridge, this includes the addition of 
more than one group to the conjoining carbon (examples in Figure 13). 
Functionalisation can also occur around the indole ring.    
Research has identified two c-DIM compounds; DIM-c-pPhOCH3 (17) and DIM-
c-pPhOH (18, Figure 13), that have exhibited cytotoxic effects towards lung 
cancer cells, potentially by acting as TR3 inactivators, thus preventing cell 
progression to the S-Phase of the cell cycle. Compounds 17 and 18 were found 
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to be active against A549 cells, with 24-hour IC50 values of 14.29 ± 2.30 μM and 
16.18 ± 1.59 μM respectively. The study also established, the DIM analogues 
were active against H460, LnCap and PC3 cell lines.[10] The H460 cell line is 
derived from non-small cell lung cancer cells, whereas LnCap and PC3 cell lines 
are derived from prostate cancer cells.  
17
19
18
 
Figure 13 – c-DIM compounds; DIM-c-pPHOCH3 (17) and DIM-c-pPhOH (18), 
which were tested on lung and prostate cancer cell lines.[10] The same research 
group investigated the effects of 17 and c-DIM-Ph (19) as Nur77 agonists.[103] 
Moreover, investigations by the same research group, demonstrated that DIM-c-
pPhOCH3 (17) and DIM-c-Ph (19) act as agonists for nerve growth factor-induced 
Balpha (Nur77) – an orphan nuclear receptor expressed in a number of cancer 
types including, colon, pancreatic, breast, prostate cancer, and interestingly, 
cerebral cells.[102] The compounds were also tested for PPARγ (peroxisome 
proliferator-activated receptor γ) activation, but the results were negative.  
Activation of Nu77 causes initiation of cell death via TRAIL (tumour necrosis 
factor-related apoptosis-inducing ligand), and cleavage of PARP (poly (ADP-
ribose) polymerase). The methoxy group on DIM-c-pPhOCH3 (17) was changed 
to the meta and ortho positions of the phenyl ring to carry out structure-dependant 
activation of Nu77 tests, whereby only the para-substituted c-DIM was found to 
be active. Furthermore, 2,2’-methyl and N,N’-methyl indole substitutions of DIM-
c-pPhOCH3 (17) and DIM-c-Ph (19) were tested and did not show Nu77 
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activation. It is also worth noting that DIM-c-pPhOH (18) was also tested in this 
study but did not demonstrate activation of either Nu77 or PPARy.[103][104]  
Moreover, Kassouf et al synthesised c-DIMs DIM-C-Ph (19), DIM-C-pPhCF3 and  
DIM-c-pPh-t-butyl, which were tested against bladder cancer cells, using PPARγ 
as a target.[106] PPARγ is a ligand activated nuclear receptor belonging to the 
nuclear hormone receptor family and is thought be a good target for anti-cancer 
therapy. Due to PPARγ activation resulting in; apoptosis, prevention of G0/G1 to 
S-phase progress, and reduced proliferation. Also, PPARγ is over-expressed in 
many different tumour samples and cell lines including lung, colon, breast and 
glioblastoma cell lines.[105] The study established that all three c-DIMs had anti-
cancer effects in vitro and in orthotopic bladder tumours in mice, DIM-C-PhCF3 
demonstrated the best activity, significantly inhibiting the growth of the orthotopic 
tumours by 32%.[106]  
Further research investigated the activity of halogenated phenyl substituted c-
DIMs; DIM-c-pPhBr and DIM-c-pPhF (20, see Figure 14), against colon cancer 
cell lines. SW480 and RKO cell lines were treated with both c-DIMs for 12 hours 
and both inhibited cell growth in vitro by activation of ER stress, caused by 
induction of CHOP (C/EBP homologous protein) and cleavage of PARP. The 
ortho- and meta- substituted analogues also exhibited activity but were much less 
potent than the para-substituted c-DIMs, the order of activity established was 
para > meta > ortho. Moreover, the 2-methyl-substituted analogues (21) and 
N,N’-methylated-substituted analogues (22) were also tested for activity. The 
former displayed good anti-proliferative activity, showing a 40-60% reduction in 
cell viability. Whereas, the latter were completely inactive – suggesting the free 
NH groups are necessary for activity, more specifically for the induction of 
CHOP.[107] 
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20 21 22   
Figure 14 - Chemical structures of DIM-c-pPhF (20) and its 2,2’-methyl 
substituted (21) and N,N’-methylated (22) derivatives.[107] 
Similar research, again involving DIM-c-pPhF (20, Figure 14) and DIM-c-pPhBr, 
concluded that both of the halogenated phenyl c-DIMs decreased cell 
proliferation and induced apoptosis in oral squamous cell carcinoma tumours.[108] 
Furthermore, as various studies have determined that aromatic-substituted c-
DIMs display anti-proliferative effects towards cancer cell lines, Tocco et al 
decided to carry out preliminary research into the activity of alkyl substituted c-
DIMs against hepatocarcinoma, the fifth most common type of primary liver 
cancer. Using the rat hepatoma cell line, FaO, the c-DIM (23), shown in Figure 
15, demonstrated a 55% reduction in cell viability at 100 μM, which was four-fold 
more potent than I3C.[109] 
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Figure 15 – Alkyl substituted c-DIM (23) tested against the FaO hepatoma cell 
line by Tocco et al.[109] 
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1.4.4 - Physiochemical properties of c-substituted 3,3’-diindolylmethane 
derivatives 
Nearly 40% of new pharmaceutical agents are associated with poor oral 
bioavailability.[110] A way of predicting whether orally administered drugs will have 
poor absorption and bioavailability, is by applying the Lipinski rule of five (Figure 
16), a method well known by medicinal chemists.[111] 
Figure 16 - Applying Lipinski rule of five to DIM-c-Ph (19), ✔ indicates rule 
applies to compound 19, whereas, ✖ indicates rule does not apply to 
compound 19.[111] 
By applying this rule to the basic aromatic substituted c-DIM, 19 (Figure 16), we 
would expect c-DIMs to have poor bioavailability, as the Log P value of DIM-c-Ph 
is thought to be around 5.40.[112] However, it is worth noting, the Lipinski rule of 
five is only applicable to compounds that are not substrates for active transports. 
Additionally, the violation of one rule, does not essentially result in poor 
absorption and bioavailability. The probability of poor bioavailability increases 
with number of rules broken and to the magnitude which they are exceeded.[111] 
The physiochemical properties of substituted c-DIMs are not seemingly widely 
documented, however, it is known that DIM has poor oral bioavailability, as a 
result of its high lipophilicity/low solubility. A study administrating DIM to rats via 
intraperitoneal injection, found DIM induced CYP-450 (cytochrome P450) to a 
much higher extent than in rats that had DIM administered orally. This is 
suggestive of poor drug absorption through the gastrointestinal tract.[113] 
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Interestingly, Safe et al carried out investigative work into the neuroprotective 
efficacy of para-phenyl substituted DIM’s (17, 18 and DIM-c-pPhCl) in a mouse 
model of Parkinson’s disease.[114] Although this study does not discuss the effects 
of c-DIMs against cancer, the study explores the pharmacokinetic behaviour of 
c-DIMs when administered orally and intravenously and states their concentration 
within brain tissues. This is of interest as one of the biggest challenges in the 
development of chemotherapeutic agents for the treatment of glioblastoma, is 
entry into the brain. Oral bioavailability was measured based on the compound’s 
total exposure.  
After oral administration, DIM-c-pPhOCH3 and DIM-c-pPhCl exhibited the highest 
oral bioavailability (38% and 42% respectively). However, DIM-c-pPhOH only 
demonstrated 6% bioavailability, potentially, due to the presence of a phenol 
group, it undergoes glucuronide conjugation as shown in Scheme 4.[114] 
 
Scheme 4 – Scheme showing glucuronidation of a phenolic group via 
nucleophilic attack to carbon of UDP-glucuronic acid. Histidine assists hydrogen 
abstraction from phenolic group.[115] 
Although the highest concentrations of the c-DIMs were found in the intestines, 
followed by the liver, reasonable distribution to the brain was observed. Oral 
administration resulted in higher compound accumulation within brain tissue than 
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intravenous administration, substantially increasing the concentration of DIM-c-
pPhOCH3 from 272 ng/mL to 1173 ng/mL. DIM-c-pPhOH showed the lowest 
concentration in brain tissue (31.2 ng/mL) with DIM-c-pPhOCH3 being the highest 
(1173 ng/mL).[114] 
This investigation demonstrates that although the solubility of c-DIM compounds 
is thought to be poor as a result of its high log P value (approximately 5.40), some 
does manage to enter the brain in in vivo studies using rats.[112][114] However, it is 
worth mentioning that results observed from using rats cannot be generalised to 
humans, thus, ideally, further research should be conducted into the 
physiochemical properties of c-DIMs in vivo, to identify how they would behave 
within the body. It is also important that the development of drug delivery methods 
for the treatment of glioblastoma are carried out, to identify effective ways to 
deliver therapeutic agents to tumour sites within the brain. For example, Safe et 
al, carried out pharmacokinetic studies into the permeability and oral 
bioavailability of two c-DIM compounds (DIM-c-pPhCN and DIM-c-pPhOCH3, 
17).  In previous research these c-DIMs had demonstrated significant anti-cancer 
effects towards several breast cancer cell lines (IC50 values in the range of 10-20 
μM across the varying cell lines).[116] The oral bioavailability of these compounds 
was less than 20%, and permeability studies suggested the permeability of these 
compounds is also poor.[116] To tackle this issue, the research team developed c-
DIM nano structured lipid carrier (NLC’s) based formulations. Using the NLC 
formulation approach, the bioavailability of the c-DIMs increased by ten-fold, 
enabling the dosage to be reduced by almost a third. Pharmacokinetic studies 
were also carried out in dogs, whereby the oral bioavailability of DIM-c-pPhCN 
increased from 27% (free drug) to 80% (NCL formulation). The reason behind 
this increase in drug oral bioavailability when using NLC formulations, is because 
there is an increased solubility in nanoparticle form. Also, nanoparticles have 
increased absorption via lymphatic and other alternative gastrointestinal uptake 
mechanisms.[116] This study shows that despite the poor oral bioavailability of the 
c-DIMs investigated, methods exist to improve the bioavailability and 
permeability, indicative that this class of compounds can still be employed in a 
clinical setting.  
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1.5 - Conclusion 
The research discussed in this section provides clear evidence of the anti-cancer 
effects of DIM and c-DIMs against several cancer types and tumours including 
pancreatic, bladder, colon and breast, via various cellular mechanisms.  On the 
contrary, the effect of DIM and c-DIMs when tested against brain tumours and 
specifically to this project, glioblastoma, is currently unknown. Thus, it seems, 
therefore necessary to carry out an investigation into the potential anti-cancer 
effects of DIM, and its methylene-substituted derivatives towards glioblastoma 
cells. 
1.6 – Project aims 
The aim of this study is to carry out preliminary research into the potential anti-
cancer activity of DIM and its symmetrical c-substituted derivatives (c-DIMs) 
towards glioblastoma.  
1.6.1 – Specific aims 
- Using DIM as the lead compound, synthesise a preliminary series of c-
DIM analogues (series one) 
- Measure the anti-cancer activity of I3C, DIM, and the compounds in series 
one, against the glioblastoma cell line U-87 MG, using the MTS cell 
viability assay.  
- Analyse the data obtained from the cell viability assays, calculate IC50 
values for the compounds tested in series one.  Determine structure 
activity relationships from the preliminary analogues. Then, synthesise a 
second series of c-DIM analogues, derived from the preliminary series 
one. 
- Measure the anti-glioblastoma activity of the second c-DIM series, again 
using the MTS assay to obtain IC50 values for each compound tested in 
series two 
- Discuss the overall structure activity relationships between compounds 
synthesised in this project, and between compounds tested for anti-cancer 
activity against glioblastoma within the Snape research group.   
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CHAPTER TWO – SYNTHETIC 
METHODS FOR C-SUBSTITUTED 
3,3’-DIINDOLYLMETHANES 
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2.1 – Introduction 
The c-diindolylmethane (c-DIM) scaffold is a privileged structure, present in many 
natural and synthetic compounds.[117] Streptindole (25, Figure 17) is derived from 
Streptococcus faecium IB 37 and is found in human waste products. Whilst, 
compounds such as vibrindole A, trisindoline (24), deoxytopsentin and 
arsindoline (23) are c-DIM structures found in marine bacteria (Figure 17).[117] 
Over recent years the synthesis of c-DIMs has gained considerable attention 
owing to their variety of bioactive properties; anticancer, antifungal, anti-
inflammatory, antibacterial and analgesic properties.[118][119]  
 
Figure 17 – Naturally occurring c-DIM derivatives.[119] 
This project will entail attempts to synthesise a number of symmetrical c-
substituted diindolylmethane analogues, after which their cytotoxic activity 
towards glioblastoma cells will then be tested and IC50 values obtained. This 
section will discuss the various synthetic methods that are available to synthesise 
c-DIMs. 
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2.2 – c-substituted 3,3’-diindolylmethanes from indole and aldehydes or 
ketones 
The most common and direct method to prepare c-substituted 3,3’-
diindolylmethane derivatives was initially pioneered by Fischer in 1886, using an 
acid catalysed Friedel-Crafts reaction. An electrophilic substitution reaction of 
indole (26) with aliphatic or aromatic aldehydes and ketones (27) yields an 
intermediate azafulvenium salt (28), which undergoes a further addition reaction 
with a second molecule of indole to form the final c-DIM (29).[120] The mechanism 
is shown in Scheme 5 below. 
26
28
29
H+ -H+ H+
-H2O27
 
Scheme 5 – Mechanism for c-DIM (29) formation, from indole (26) reacting with 
a carbonyl compound. 
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The following reactions follow the same mechanism, confirming the intermediate 
azafulvenium salt formed in the production of c-DIMs. For example, the 
intermediate formed during a reaction between 3-formlindole (30) and indole (26) 
in the presence of HClO4 or HCl, was isolated and identified as the formation of 
urorosein salt (31, Scheme 6).[121] 
indole
HX
urorosein salt
30 31
 
Scheme 6 - Reaction scheme showing the intermediate (31) isolated from an 
acid catalysed reaction between 3-formindole (30) and indole (26).[121] 
Similarly, when isobutylaldehyde reacts with N-methylindole (32) with TFA in 
toluene for 10, 20, 60 and 120 minutes, under microwave conditions, 3-vinylindole 
(34) and bisindolylalkane (35) were produced via the azafulvenium intermediate 
(33), in ratios of 80:20, 90:10, 96:4, and 100:0 respectively (Scheme 7).[122] 
-H+
TFA, MW
32 34
35
1-methylindole
- 1-methylindole
33
 
Scheme 7 - Reaction between isobutylaldehyde and N-methylindole (32).[122] 
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The condensation of indoles with carbonyl compounds is typically catalysed by 
protic acids or Lewis acids. Protic acids usually employed include; H2SO4, TFA, 
HCl and oxalic acid, and popular Lewis acids used are AlCl3, InCl3 and 
BF3·Et2O.[123][124] Research by Wang et al investigated the efficiency of a variety 
of Lewis acids in the reaction between benzaldehyde and indole, whereby 
zirconium tetrachloride prevailed in terms of reaction rate and yield (30 minutes, 
96%).[125] However, many Lewis acid catalysts are required in excess of 
stoichiometric amounts due to these acids being susceptible to decomposition or 
deactivation in the presence of nitrogen containing compounds. This can be 
avoided by using lithium perchlorate, although this can involve extensive reaction 
times and can be expensive. Additionally, Lewis catalysts can involve long 
reaction times and are usually not environmentally benign.[126] As a result, many 
alternative catalysts have been developed. 
Ionic liquids have gained interest as catalysts, due to their easy recyclability and 
negligible vapour pressure. Vadhat et al developed a protocol for the synthesis 
of c-DIMs at room temperature, using ethyl ammonium nitrate as a catalyst in 
water with yields of up to 95%.[127] Other ionic liquids employed include 
[Et3NH][HSO4], [bnmim][HSO4] and [Msim]Cl.[128][129][130] 
More recently, the employment of Lewis acid – surfactant-combined catalysts 
(LASC’s) has become attractive for the synthesis of c-DIMs from indole and 
aldehydes or ketones in water, because being able to obtain high yields using 
water as a solvent means the use of hazardous organic solvents can be avoided. 
LASC’s act as an acid catalyst and increase the solubility of indole in water by 
acting as surface-active agents, forming a stable colloidal dispersion system. 
Examples include dodecylsulfonic acid (DSA) and dodecylbenzenesulfonic acid 
(DBSA).[131]  
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Veisi et al reports the use of in situ generated iron(III) dodecyl sulfate (Fe(DS)3), 
as an efficient LASC for the synthesis of c-DIMs (29) from indole (26) and 
aldehydes or ketones (27) in water (Scheme 8), yields of 85-95% were 
obtained.[132]  
26
In situ generated Fe(DS)3
H2O, r.t. 29
27
Scheme 8 – Synthesis of c-DIMs in water using an in situ generated iron(III) 
dodecyl sulfate LASC.[132] 
Numerous zeolites have been reported to efficiently promote the synthesis of c-
DIMs from indoles and aldehydes.[133] Karthik et al investigated the efficiency of 
zeolites HY, Hβ and H-ZSM-5 for the synthesis of vibrindole A. All zeolites 
demonstrated excellent catalytic activity in the order HY>Hβ>H-ZSM-5, which is 
in accord with the acid site density of the zeolite. The catalysts could be used up 
to five times without loss of activity with yields of up to 88%.[134] Although eco-
friendly, zeolite catalysts can often require high activation temperatures.  
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Research by Malik et al identified that iodine catalysed synthesis of c-DIMs from 
indole (26) and unsaturated α,β-ketones (35) in ethanol, produced yields of 52-
63% over 4 hours. The c-DIMs (29) were produced via the formation of an 
azafulvenium salt (36); the reaction mechanism can be seen in Scheme 9.[135] 
26
I2
Ethanol
H-OEt
36
29
35
 
Scheme 9 – Synthesis of c-DIMs from indole (26) and an α,β-unsaturated 
ketone (35).[135] 
Zahran et al present an efficient synthesis of 2-subsituted c-DIM analogues using 
glacial acetic acid as a catalyst under microwave irradiation.[136] The results show 
excellent reaction times between 1-10 minutes and moderately good yields (56-
96%), shorter reaction times and higher yields were observed for the reaction of 
indole with aromatic aldehydes. However, the use of aliphatic aldehydes resulted 
in longer reaction times and lower yields. The study also states that heating by 
microwave irradiation produced much higher yields than conventional heating.[136] 
Further research by Das demonstrates the synthesis of c-DIM derivatives by 
reaction of indole with aldehydes and ketones, using [(n-propyl)2NH2][HSO4] ionic 
liquid catalyst and microwave irradiation. c-DIMs were produced in extremely high 
yields (85-99%) in under 6 minutes.[137]  
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Furthermore, numerous syntheses involving ultrasound irradiation in the 
production of c-DIMs have been reported. Joshi et al state the synthesis of c-DIM 
analogues from indole and aromatic aldehydes in water, using 1-hexenesulfonic 
acid sodium salt to catalyse the reaction. The reaction mixture underwent ultra 
sonic waves for 45 minutes and produced good yields of 82-94%.[138] Similarly, Li 
et al reports the ultrasound assisted synthesis of N, N’-dimethyl c-DIM derivatives 
(38) by reaction of N-methylindole (32) with benzaldehyde (37) in water, 
dodecylbenzenesulfonic acid was employed as a catalyst, and the reaction 
mixture was put under ultrasound irradiation at 23-25 oC (Scheme 10).[139] 
Dodecylbenzenesulfonic acid/ H2O
u.s./23-25 oC
32 38
37  
Scheme 10 – Ultrasound assisted synthesis of N-methylindole (32) and 
benzaldehyde (37) to yield N,N’-dimethyl c-DIM (38).[139] 
In addition to microwave and ultrasound irradiation, the photochemical synthesis 
of DIM derivatives has been reported. D’Azuria synthesised 2-substituted c-DIM 
analogues (40) by reaction of indole or 2-methylindole (39) with aldehydes or 
ketones (27) in acetonitrile (see Scheme 11). Yields of 47-52% were 
observed.[140]  
CH3CN
hv
39
40
27
Scheme 11 – Photoirradiation c-DIM synthesis.[140] 
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It is also worth noting, the formation of c-DIMs in the absence of catalyst in 
glycerol at 90 oC also has been observed. He et al investigated the use of glycerol 
in the electrophilic activation of aldehydes. Yields as high as 98% were obtained 
for aromatic substituted c-DIMs, featuring methyl substitution at position-2 of the 
indole rings (Scheme 12).[141]  
39
Catalyst-free
glycerol, 90 oC
42
41
Scheme 12 – Preparation of 2,2’-dimethyl c-DIMs (42) from 2-methylindole (39) 
and various aldehydes (41), using glycerol as a reaction medium.[141] 
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2.3 – c-DIMs from indoles with alcohols, amines and related compounds 
Although these methods are less frequently employed, the synthesis of c-DIMs 
has been achieved without the use of aldehydes or ketones. This section will 
discuss alternative pathways towards the production of symmetrical c-DIM 
derivatives. 
 
2.3.1 – c-DIMs from indoles and alcohols 
Hikawa et al has developed a unique method of c-DIM synthesis by the reaction 
of indole-5-carboxylic acid (43) with benzyl alcohols (44) in the presence of a 
palladium catalyst (Pd(OAc)2) in water (Scheme 13).[142] The study states that the 
reaction proceeds as water protonates the hydroxyl group of the benzyl alcohol 
which leads to the formation of a (η3-benzyl)palladium intermediate, which then 
undergoes transformation reactions to produce 5-carboxylic acid c-DIMs (45) in 
good yields (63-93%).[142] 
43
Pd(OAc)2
H2O, 60 
oC
3 eq.
44
45
 
Scheme 13 – Synthesis of 5-carboxylic acid c-DIMs (45) via indole-5-carboxylic 
acids (43) with benzyl alcohols (44) in water.[142] 
Research by Bandgar et al synthesised a library of c-DIM analogues by the 
reaction of indole (26) with 1H-indole-3-yl-(phenyl)methanol (29) and its 
derivatives, under solvent free conditions at room temperature and catalysed by 
HBF4-SiO2 (Scheme 14). Although the reaction was successful, producing good 
yields (75-90%) and short reaction times (10 minutes), the same research group 
report c-DIM synthesis involving the condensation of indoles with aldehydes 
which produced higher yields (85-94%) and the same reaction time.[143]   
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46 1926
HBF4-SiO2 
Neat, rt, grinding
 
Scheme 14 – Preparation of DIM-c-Ph (19) using 1H-indole-3-yl-
(phenyl)methanol (46) and indole (26).[143] 
The one-pot conversion of primary alcohols (47) to their corresponding c-DIM 
(19), has been carried out by Khosropour et al, under solvent-free conditions and 
promoted by Bi(NO3)3 ·5H2O (Scheme 15). The reactions proceeded in under 6 
minutes and demonstrated excellent yields of up to 95%. Additionally, when 
secondary alcohols (48) were added to the reaction mixture, none of these 
alcohols produced their corresponding c-DIMs (49), suggesting the reaction is 
chemoselective towards primary alcohols.[144] 
Indole, Bi(NO3)3 ·5H2O 
4 min
47 48
49, 0%19, 90%  
Scheme 15 – Reaction scheme showing the chemoselective reaction of primary 
(47) and secondary alcohols (48) with indole (26).[144] 
Similarly, Nikoofar also reports the one-pot synthesis of c-DIMs from primary 
alcohols. The reaction was carried out in an undivided electrochemical cell, using 
acetonitrile as a solvent and LiClO4 as a catalyst. The alcohol is oxidised at the 
anode, yielding the corresponding aldehyde, for example, benzyl alcohol is 
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oxidised to benzaldehyde. Upon addition of indole to the reaction mixture, the 
indole anion is formed via cathodic electron absorbance, leading to nucleophilic 
attack of indole to the aldehyde to yield the desired c-DIM.[145] 
2.3.2 – c-DIMs from indoles and amines, imines or related derivatives 
A variety of c-substituted diindolylmethane derivatives were prepared by Yang, 
by the CuBr catalysed cleavage of C-N bonds in the oxidative cross-
dehydrogenative-coupling of various N-benzylamines (50) with indoles, in the 
presence of tert-butyl hydroperoxide. N-Benzyl pyrrolidine produced the highest 
yields (61-80%), its derivatives; N-(3-methylbenzyl) pyrrolidine and N-(4-
chlorobenzyl) pyrrolidine produced moderately good yields – possibly due to 
steric hinderance. However, when N-ethyl pyrrolidine was employed, no DIM 
product was observed. The exact mechanism for this reaction is unknown, 
although a plausible pathway can be seen in Scheme 16. The initial step is 
thought to be an iminium ion (51) being formed through the development of a 
copper complex. Secondly, a Friedel-Crafts type reaction yields the intermediate 
(52), then two possibilities for the transformation of 52 to 19 exist; either a 
substitution (SN2) reaction or an elimination reaction followed by a Michael 
addition. Intermediates 52 and 53 were both present in the reaction mixture after 
the reaction, suggesting the latter is more probable.[146] 
 
CuBr, TBHP
SN2
19
Elimination
51
Addition
52
53
50
 
Scheme 16 – A plausible pathway for the synthesis of c-DIM 19 via N-
benzylamines (50) and indole (26).[146] 
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Similar work was carried out by Gopalaiah, his team synthesised 27 different c-
DIM analogues via the oxidative coupling of benzylamines with indole.[147] The 
reaction was promoted by iron(II) triflate in chlorobenzene, in an atmosphere of 
molecular oxygen at 110 oC. Scheme 17 shows the reaction between 
benzylamine (54) and indole (26) to produce compound 19. Yields of up to 93% 
were obtained, the electronic substituents of the aromatic benzylamines did not 
significantly reduce the yield, except for a trifluoromethyl group at the meta 
position of the benzylamine. Secondary benzylamines worked efficiently as 
substrates with yields of 74%, whereas aliphatic amines, for example octylamine 
and hexylamine, produced significantly lesser yields; 55 and 48% 
respectively.[147] 
Fe(OTf)2
Chlorobenzene
110 0C, O2
54
1926
Scheme 17– Indole (26) reacting with benzylamine (54) to produce c-DIM 
(19).[147] 
Imines are much less reactive towards nucleophiles in comparison to ketones 
and aldehydes, however there are reports of imines reacting with N-indoles to 
produce c-DIMs in decent yields. For example, Xie et al have developed an 
efficient procedure for the synthesis of c-DIMs (Scheme 18) by reacting various 
imine derivatives (55) with N-methylindole (32), using a dithiocarbohydrazone 
Schiff base (Zn(ClO4)2·6H2O). Initially, R2 of the imine were aromatic substituents 
and gave high yields of 86-99%, regardless of whether R1 was an electron-
donating or electron-withdrawing group. However, the use of hydroxyl imines 
produced considerably lower yields (63-73%).[148] 
32 5655
Zn(ClO4)2·6H2O
DCM, r.t, 10 hours
 
Scheme 18 – Friedel crafts alkylation of imine (55) with N-methylindole (32).[148] 
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Typically, nucleophilic substitution of amines, alcohols and chemically similar 
compounds with indole, results in the alkylation of indoles. However, when Ballini 
et al attempted the alkylation of 2-methylindole (39) using α-amido sulfones (57), 
in the absence of solvent and catalysed by K-10 montmorillonite clay, c-DIMs (58) 
were unexpectedly produced in 58% yield (Scheme 19).[149] 
5838
57
 
Scheme 19 – Synthesis of 2-substituted c-DIMs (58) from 2-methylindole (39) 
and α-amido sulfones (57).[149] 
In addition to amines and imines, nitrones can also react with indoles to form c-
DIMs. Vallee et al synthesised symmetrical c-DIM derivatives by reacting the 
benzylnitrone of propanal (59) with indole (26) at room temperature in the 
presence of TfOSiMe3, in anhydrous DCM for 2 hours (Scheme 20).[150] Once the 
reaction had reached completion, 3-[1-(1H-indol-3-yl)propyl]-1H-indole (23) was 
the major product formed with a yield of 70%, However, some indole dimer was 
also formed (60, 5%). This by-product is the result of the triflic acid formed from 
the catalyst protonating indole which then attacks another indole molecule. 
Although it was a minor product, the similarity in Rf value made it inseparable 
from the major product by flash column chromatography (FCC). To counter this 
problem, TfOSiMe3 was substituted for the use of ClSiMe3 whereby the desired 
c-DIM (23) was produced in 85% yield and the indole by-product was not 
detected.[150]  
 
 
 
 
 
 
 
 
39 
62 
 
26
59
23
60
H+
TfOSiMe3
0 oC, anhydrous DCM
+26
 
Scheme 20 – Reaction between the benzyl nitrone of propanal (59) and indole 
(26) to produce c-DIM (23) and by-product (60).[150] 
 
Applying the same strategy, the same research group synthesised a naturally 
occurring c-DIM analogue (63), which is derived from the marine sponge Orina 
Sp. with a yield of 85%. The reaction scheme they used can be seen below. 
(Scheme 21).[151] 
26
63
61
62
ClSiMe3
CH3CN
1. CF3CO2H in DCM
2. NaHCO3
Scheme 21 – Utilization of nitrone (61) with indole (26) to develop c-DIM (62), 
derived from marine sponge Orina Sp.[151] 
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2.4 – Conclusion 
Such an extensive range of synthetic methods are available for the preparation 
of c-DIMs and their derivatives. However, this project will use the condensation 
of indoles with aldehydes or ketones to synthesise a library of c-DIM analogues, 
as it is an extremely direct and well understood method, which can be carried out 
in the absence of non-green organic solvents. It also involves the use of many 
readily available and inexpensive reagents and catalysts. The reaction between 
indoles with aldehydes and ketones can be employed to develop a wide variety 
of c-DIMs to be tested against glioblastoma cell lines.  
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CHAPTER THREE – RESULTS 
AND DISCUSSION 
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3.1 – Synthetic results and discussion 
3.1.1 - Compound synthesis 
As previously mentioned in chapter two, there are many synthetic routes available  
to produce symmetrical c-DIM compounds. However, this project employed the 
electrophillic substitutuion of indoles with various aldehydes and ketones – a very 
direct and well understood method.[120] The compounds shown in Scheme 22, 
were catalysed by concentrated sulfuric acid; the first 5 compounds (19, 17, 64, 
65 and 20) shown in Scheme 22 were carried out using water as a reaction 
medium, as the reactions proceeded well in water and produced good yields. 
Using water in replacement of an organic solvent offers advantages such as; safe 
handling, reduced expense and environmental compatability. However, for the 
synthesis of compounds 66 and 67 the use of water was not possible. Water was 
not a suitable reaction medium for the synthesis of 66 and 67 due to the 
insolubility of the reagents 2-methylindole and 2-phenylindole in water. Therefore, 
reaction conditions were optimised.  
 
 
Scheme 22 - Reaction scheme for c-DIM compounds (19, 17, 64, 65 and 20) 
and 2,2’-substituted c-DIM compounds synthesised (66 and 67), and yields. 
 
Compound C1 C2 R1 Yield (%) 
19 Ph H H 88 
17 PhpMeO H H 58 
64 PhpNO2 H H 73 
65 Me Me H 38 
20 PhpF H H 71 
66 Ph H Me 65 
67 Ph H Ph 72 
2
H2SO4
66 
 
Scheme 23 below, shows reaction mechanism employed for the formation of 
compound 19, occurring by an acid catalysed Friedel-Crafts alkylation reaction 
between indole and benzaldehyde. 
H+ H-
H+
-H2O
26
39
19
 
Scheme 23 – Reaction mechanism for the synthesis of compound 19 via the 
reaction of indole (26) and benzaldehyde (39). 
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The reaction between indole (2 eq.) and benzaldehyde yielded compound 19 
(Scheme 23). Compound 19 then underwent N,N-dimethylation in dried THF to 
produce compound 38. Methyl iodide is a popular methylation reagent used in 
organic synthesis, as the iodide ion is an excellent leaving group, thus N-
methylation reactions using methyl iodide often have high conversion rates. Also, 
the low boiling point of methyl iodide (42 oC), means that it can be removed from 
the reaction mixture with ease in vacuo. Likewise, NaH is also easily removed 
from the reaction, during the acidic 1 M aqueous HCl extraction, by being miscible 
with the aqueous phase. This reaction proceeded well and produced a decent 
yield of 79% (Scheme 24). The formation of this compound was identifiable by 1H 
NMR by the loss of the N-H peak and the appearance of a CH3 peak, integrating 
to 6 H at 3.70ppm. 
H2SO4
H2O
NaH, 3 eq. MeI
THF
2
19
38, 79%
 
Scheme 24 - Synthesis of compound 38 via N,N’-methylation of compound 19. 
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3.1.2 - Attempted synthesis and optimisation of synthesis 
3.1.2.1 - Optimisation of synthesis for 3-[1-(1H-Indol-3-yl)-1-methyl-ethyl]-
1H-indole (Compound 65) 
26 69
65
2
H2O
H2SO4, reflux 
 
Scheme 25 - Attempted synthesis of 3-[1-(1H-indol-3-yl)-1-methyl-ethyl]-1H-
indole (65). 
To begin with, the reaction shown in Scheme 25 was carried out to synthesise 
65. However, after 3 days stirring no reaction was observed. 
Next, the same reaction was carried out, however heat (50 oC) was applied to the 
reaction. Due to the low boiling point of acetone (69), an air cooled reflux 
condenser was used to prevent the evaporation of acetone whilst under heating. 
Still, no substantial product (65) was observed. 
It was clear that heating the reaction mixture made a slight improvement on the 
reaction, however the lack of product formed prompted the use of an excess of 
acetone (2 mL), as it would not have a detrimental effect on the reaction. The 
heat of the reaction mixture was increased to 60 oC. After 4 days a reasonable 
amount of product was visible by TLC and the reaction was stopped.  
Purification was an issue with this compound. Initially, it seemed only two 
products were present by TLC, however when separated by flash column 
chromatography (40:60 ethyl acetate: petroleum ether) the 1H NMR showed a 
mixture of products. After experimenting with various TLC solvent systems, a TLC 
was ran in 8:92 ethyl acetate: toluene and was stained using p-anisaldehyde. 
When gently heating the TLC after staining, two different coloured products (pink 
and purple) were visible within what initially seemed to be one product. Flash 
column chromatography was then carried out again using 8:92 ethyl acetate: 
toluene to yield compound 65. 
The use of a ketone in this reaction, as opposed to an aldehyde made it more 
difficult to obtain the desired c-DIM and resulted in a lower yield. Firstly, due to 
steric effects. Ketones have two groups attached to the carbonyl carbon, 
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therefore, steric hinderance impedes nucleophilic attack of the carbonyl carbon. 
Secondly, as a result of electronic effects. As the carbonyl group in ketones is 
attached to two groups, the partial positive charge of the carbonyl carbon is less 
than that of an aldehyde.  
3.1.2.2 - Optimisation of synthesis for 2-Methyl-3-[(2-methyl-1H-indol-3-yl)-
phenyl-methyl]-1H-indole (66) and 2-Phenyl-3-[phenyl-(2-phenyl-1H-indol-
3-yl)methyl]-1H-indole (67) 
39
69 39
66 67
Unsymmetrical c-DIM
H2SO4
DCM
 
Scheme 26 – Attempted synthesis of 66 and 67 in the same reaction. Due to 
solubility issues of the products, purification via flash column chromatography 
was not possible. 
Originally, an attempt was made to synthesise both compounds 66 and 67 in the 
same reaction mixture, with the intention of purifying the products by flash column 
chromatography in order to obtain three different 2,2’-substituted c-DIMs. Due to 
the insolubility of 2-methylindole and 2-phenylindole in water no reaction was 
observed.  
Then, the reaction solvent was changed to DCM as the 2-indole reagents were 
soluble in this, the reaction scheme can be seen in Scheme 26. During this 
reaction a solid precipitated out. The crude 1H NMR showed the formation of a 
mixture of products. Due to the insolubility of the crude product in common 
solvents such as DCM, ethyl acetate, petroleum ether, diethyl ether, the product 
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was extremely difficult to purify by flash column chromatography. This issue of 
solubility also made it problematic to follow the reaction by TLC.  
Therefore, for ease of purification, the reactions were carried out separately. 
Again, due to the insolubility of the products, they were not identifiable by TLC. 
However, the depletion of 2-methylindole and 2-phenylindole from the reaction 
mixtures were visible by TLC. The desired 2,2’-substituted c-DIMs precipitated 
out in the reaction mixture, the product was filtered and washed with 20:80 ethyl 
acetate: DCM to yield products 66 and 67.  
 
3.1.2.3 - Attempted synthesis of 3-[1H-Indol-3-yl(diphenyl)methyl]-1H-
indole (68) 
 
Scheme 27 - Attempted synthesis of 3-[1H-indol-3-yl(diphenyl)methyl]-1H-
indole (68) 
The reaction scheme above was attempted, however no reaction was observed. 
Similar to compound 65, due to the steric hinderance of two benzene rings around 
the carbonyl group of benzophenone, this ketone was not easily susceptible to 
nucleophilic attack. Additionally, the partial positive charge of the carbon is 
reduced by the benzene groups attached to the carbonyl carbon, therefore the 
desired product was not formed during this reaction.  
The same reaction was carried out in using amberlyst-15 as a catalyst, however, 
thought to be due to the same reasons of steric and electronic effects, no product 
was formed.  
 
 
 
2
26
68
76
H2SO4
DCM, reflux
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3.1.3 - Challenges encountered in compound synthesis 
Compounds 64, 66 and 67 presented solubility issues with regards to carrying 
out NMR analysis. DMSO was the only NMR solvent found that the compounds 
would dissolve in to a sufficient extent. For example, the high molecular weight 
of compound 67 (474 Da), meant a high concentration sample was required for 
13C and DEPT-135 NMR analysis.  
When analysing the 13C NMR and DEPT-135 spectra, it became apparent that 
the peak of the C-H bond of the bridge joining the indole rings, was masked by 
the broad DMSO solvent septet, however, the C-H peak was clearly visible in the 
1H NMR spectrum. Analysing the 13C and DEPT-135 NMR of structurally similar 
compounds 19, 17, and 20, which were soluble in deutrerated chloroform, the CH 
bridge peaks are visible at 40.2, 39.3 and 38.9 ppm respectively. Figure 18 shows 
that in the 13C NMR of compound 64, the DMSO solvent peak covers the range 
you would expect the CH bridge peak to lie.  
 
 
Figure 18 - 13C NMR of compound 64. The CH peak of compound 64 is 
assumed to be hidden underneath the DMSO solvent peak. 
C-H peak 
masked by 
DMSO solvent 
peak (39.0 - 
40.7ppm)  
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To counter this issue, DEPT-90 NMR was run for compounds 64, 66 and 67. As 
DEPT-90 spectra only show CH peaks, DMSO was not visible, meanwhile, the 
desired CH peaks were. See Figure 19, for DEPT-90 NMR spectrum of 
compound 64. 
 
Figure 19 – DEPT-90 NMR of compound 64, the CH peak was visible on a 
DEPT-90 NMR spectrum, as only CH peaks are seen. 
 
 
 
 
 
 
 
 
 
C-H visible at 
39.9ppm  
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3.2 - Cell viability results and discussion 
3.2.1 - Materials  
Ethanol, 96 well plates, 75 cm2 angled neck tissue culture flasks, 15 mL and 50 
mL centrifuge tubes, serological pipettes, PBS (phosphate buffered solution) 
tablets, foetal bovine serum were purchased from ThermoFisher Scientific. 
Sterile DMSO was purchased from Sigma-Aldrich. Eagles Minimum Essential 
Medium (EMEM), non-essential amino acids, trypsin and sodium pyruvate 
solution were purchased from Lonza. The U87-MG human glioblastoma cell line 
was originally from ECACC. MTS assay; CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay was purchased from Promega Corporation.  
A Matic AE2000 microscope was used for observing and counting cells. 
Absorbance was measured at 485 nm using a GENios pro plate reader with 4 
seconds shaking.  
 
3.2.2 - Cell culture methods 
3.2.2.1 - Defrosting cells 
Wearing gloves and a full face shield, a vial of cryopreserved U-87 MG cells were 
removed from -180 oC liquid nitrogen. Cells were stored in dry ice whilst being 
transported to the tissue culture laboratory. Cells were then held in a 37 oC water 
bath, carefully as to not submerge the vial under the water as this can encourage 
contamination. Once defrosted, the vial of cells were placed in the fume hood and 
carefully pipetted into a 75 cm3 flask. 10 mL of EMEM was then added and the 
contents of the flask was resuspended by gently pipetting up and down, to ensure 
the cells were dispersed in the media. Cells were then viewed under the 
microscope and incubated at 37 oC in a humidified atmosphere with 5% CO2, until 
they had reached 75-85% confluence and passaging was required.  
3.2.2.2 - Cell maintenance 
U-87 MG cells were maintained in Eagles Minimum Essential Medium (EMEM-
500 mL) supplemented with 10% foetal bovine serum (FBS-50 mL), L-glutamine 
(2 nM-5 mL), 1% non-essential amino acids (NEAA-5 mL) and sodium pyruvate 
(1 mM-5 mL) and incubated at 37 oC in a humidified atmosphere with 5% CO2. 
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When an average of 75-85% confluence was reached, cells were washed with 5 
mL PBS solution, which was then aspirated. 2 mL of 1x trypsin was added and 
cells were returned to the incubator to detach the from flask for 3-5 minutes. Cells 
were observed under the microscope to ensure they had detached and 2 mL of 
supplemented EMEM was added. Cells were transferred to a 15 mL centrifuge 
tube and centrifuged at 1000rpm for 5 minutes, subsequently the supernatant 
was removed. Cells were either resuspended in an appropriate media volume 
and passaged into suitable ratios. Or a single cell suspension was obtained, and 
cells were seeded into 96 well plates for experimental analysis.   
3.2.2.3 - MTS cell viability assay 
The protocol for the MTS assay, which is explained below, was provided by the 
manufacturer; Promega, and was followed extremely carefully.[152] The MTS 
assay is a colorimetric technique based on the reduction of a tetrazolium dye by 
NAD(P)H-dependent dehydrogenase enzymes in mammalian cells. MTS is 
reduced to a formazan product (Scheme 28), causing a colour change (yellow to 
brown) which can be quantified by measuring absorbance at 485 nm, providing 
a measure of cell viability. The colour change to brown indicates a high quantity 
of living cells, whereas yellow means the majority of cells are dead (or non-
viable).  
MTS 
(yellow)
Formazan
(brown)  
Scheme 28 – Reduction of MTS to the formazan product.[145] 
Concentrations of 250 µM, 100 µM, 10 µM of and 1 µM of I3C, DIM and the c-
DIM compounds were prepared in aseptic conditions using sterile DMSO and 
media.  
This was carried out by serial dilutions; the serial dilution scheme followed is 
shown in Figure 20. Firstly, a 200 mM stock solution one was made. From this, 
50 µL was taken and diluted with 450 µL DMSO to create 20 mM stock solution 
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two. Then a 10,000 µM working solution was made by taking 250 µL of stock 
solution 2 and diluting it with 250 µL media. 12.5 µL of the working solution was 
taken and made up to 0.5 mL with media to create the 250 µM concentration. 5 
µL of the working solution was taken and again made up to 0.5 mL with media to 
make the 100 µM concentration. From the 100 µM concentration 50 µL was taken 
and 450 µL media added to make the 10 µM concentration, this serial dilution 
was repeated twice to make the 1 µM and 0.1 µM concentrations.  
 
Figure 20 - Serial dilution scheme followed to prepare the 250 µM, 100 µM, 10 
µM and 1 µM concentrations of I3C, DIM and the compounds synthesised. 
Before cells could be seeded for experimental analysis, a cell count was 
performed. After the cells are centrifuged and a single cell suspension is created, 
10 µL was removed and combined with 10 µL trypan blue. Trypan blue is a 
negatively charged chromophore with the inability to penetrate the cell membrane 
of live cells, therefore distinguishing between live and dead cells. The living cells 
in the solution of trypan blue were counted using a haemocytometer. The value 
of living cells obtained from the haemocytometer x 104 equals the number of cells 
per mL of the cell suspension. This number is multiplied by 2, to correct for the 
dilution with trypan blue to give the total number of cells in the cell suspension.  
To calculate what volume of the cell suspension was required to seed cells at 
2000 per well, the total number of cells was divided by 2000 to give the value of 
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2000 cells per mL, dividing this value into 1000 then times by the number of wells 
provides the volume of cell suspension needed to seed 2000 cells per well. This 
volume was taken from the cell suspension and diluted to 10 mL with media. 100 
µL of the new stock solution was carefully pipetted into each well on the plate 
except for the media only wells, as these wells do not need cells (Figure 21). 
 
Figure 21 – Plate map for cell viability experiment. Control wells = cells and 
media. Media wells = media, no cells. 
Once cells were seeded at 2000 cells per well in 100 µL EMEM, they were 
incubated for 24 hours. Next, the media was aspirated from each well except from 
the media wells. 100 µL of each concentration (250 µM, 100 µM, 10 µM of and 1 
µM) of I3C, DIM and the compounds was added to the appropriate well on the 
plate (See Figure 21). 100 µL of media was added to the control and media wells. 
Then, the DMSO control wells (0.5% and 1.25%) were also added in a 100 µL 
volume. The plate was then incubated for 48 hours. Once treatment was 
completed, 10 µL MTS reagent per well was added and the plate was incubated 
for 1 hour. Subsequently, the plate was transported to the plate reader wrapped 
in foil, as MTS reagent is light-sensitive. The absorbance was measured at 485 
nm with 4 seconds of shaking using a 96 well plate reader.  
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3.2.2.4 - Statistical analysis 
Statistical analysis was carried out using excel 2016. Results from each assay 
were normalised and expressed as a percentage of untreated cells for each 
concentration using equation 1. Absorbance values were expressed as the mean 
value of at least 3 assays in triplicate from different cell passages. Anomalous 
results were discounted if they were outlying from the mean value by 1 standard 
deviations.  
𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝑀𝑒𝑑𝑖𝑎 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝐷𝑀𝑆𝑂 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝑀𝑒𝑑𝑖𝑎 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝑥 100 = 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) 
Equation 1 – Cell viability (%) equation. 
 
3.2.3 – Series one cell viability results and discussion 
3.2.3.1 – Cell viability assay 
The cell viability for I3C, DIM and the compounds synthesised was tested against 
U-87 MG human glioblastoma cells. This was measured using the MTS assay, 
this utilizes a colorimetric method for the quantification of viable mammalian cells. 
The MTS tetrazolium compound is reduced to a formazan dye by viable cells, 
which causes a colour change from yellow to brown. This colour change accounts 
for the amount of viable cells present in the cell culture, measuring the 
absorbance allows the cell viability to be quantified. Using the cell viability values 
obtained, cell viability graphs can be constructed, from which, IC50 values can be 
calculated for each compound tested. For example, Graph 1 shows the cell 
viability graph for DIM. The IC50 of a compound determines the concentration of 
the compound required for 50% inhibition of cancer cell lines. Once IC50 values 
are obtained, it is possible for comparisons between the compounds to be made, 
as well as against the clinically relevant drug temozolomide. 
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Graph 1 - Cell viability graph of U-87 MG cells after treatment with DIM after 48 
hours. 
This section will entail the IC50 values obtained for I3C, DIM and the compounds 
synthesised, alongside why the compounds from series one and two were 
synthesised and tested. Also, the structure activity relationship of the compounds 
with regards to their anti-proliferative effects towards U-87 MG cells will also be 
discussed. Cell viability results from series one and series two will be compared 
to compounds previously tested against glioblastoma cell lines within the Snape 
research group. 
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3.2.3.2– Series one cell viability results 
Compound Chemical Structure IC50 (µM) 
I3C 
 
158 
DIM 
 
46 
19 
 
32 
17 
 
52 
64 
 
38 
65 
 
33 
Table 3 – IC50 values for I3C, DIM and compounds 19, 17, 64 and 65 against 
the U-87 MG cell line for 48 hours. 
As this project aimed to investigate whether DIM and its c-DIM derivatives display 
anti-cancer effects towards glioblastoma, series 1 consisted of preliminary 
compounds to test, including I3C and DIM (Table 3). This made it possible to 
establish whether DIM is active and compare its activity to I3C. Obtaining an IC50 
for DIM will also enable the evaluation of the effect substitution on the methylene 
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bridge has on activity. Compound 19, with a phenyl group on the methylene 
bridge, acts as the neutral compound of the c-DIM series and will determine 
whether aromatic substituted c-DIMs demonstrate activity against the 
glioblastoma cell line. Then, compound 17 featuring a para-methoxy group on the 
phenyl ring, explores the effect of an electron donating group on the phenyl ring, 
as the lone pair on the oxygen delocalises into the ring. On the contrary, 
compound 64 bears a para-nitro group on the ring which heavily decreases the 
electron density of the aromatic ring as it draws electrons towards itself, away 
from the ring. Compound 65 investigates whether the introduction of two alkyl 
groups on the methylene bridge will affect the anti-cancer effects, and if so, in 
what capacity when compared to aromatic-substituted c-DIM compounds 19, 17 
and 64. 
3.2.3.3 - Series one cell viability discussion 
As shown in Table 3, DIM displayed much better activity than I3C, (DIM 46 µM 
vs I3C 158 µM). This could possibly be due to I3C itself being active, or potentially 
and more likely, be the result of the conversion of I3C into its condensation 
product, DIM. Literature states that I3C rapidly converts into DIM at low pH and 
converts into DIM slowly at neutral pH.[153][154] Therefore, as tissue culture 
medium is approximately pH 7-7.7, the activity of I3C stated in Table 3 may 
actually be due to the slow conversion of I3C to DIM in vitro. The IC50 values 
obtained for I3C and DIM are accordance with literature involving other cancer 
cell lines. For example, Moiseeva et al report IC50 values of 300 µM and 100 µM 
for I3C and DIM respectively when tested against breast cancer cell lines.[155] 
Additionally, when I3C and DIM were tested against prostate cancer cell lines the 
IC50 values were 50 µM (DIM) and 150 µM (I3C).[156]  
With regards to the c-substituted DIM derivatives, each of the compounds 
synthesised in series one, all demonstrated good activity against the glioblastoma 
cell line, with barely a difference between aromatic and alkyl substituents (32 µM 
compound 19 vs 33 µM compound 65).  
Compound 19, the neutral c-DIM, displays very good activity against 
glioblastoma, this is consistent with the literature formerly discussed that c-DIMs 
demonstrate anti-proliferative activity against many types of cancer cells. The 
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IC50 of compound 19 is a great improvement on that of I3C and is a small degree 
better than DIM, suggesting the incorporation of substituent on the methylene 
bridge of DIM slightly improves the anti-cancer effect. When comparing 
compound 19 to compounds 17 and 66, the contrasting electronic effects of the 
methoxy and nitro groups on the phenyl ring do not seem to majorly effect the 
anti-cancer activity, however, it is worth noting the electron donating methoxy 
group very slightly reduces the activity (32 µM [-H] and 38 µM [-NO2] vs 52 µM [-
OMe]).   
Analogue 65, with a gem-dimethyl group, also has respectable activity against 
the glioblastoma cell line. There essentially no difference observed between 
alkyl-containing compound 65 and phenyl-containing compound 19 (33 µM and 
32 µM, respectively). 
Overall, series one determines that both aromatic-substituted and alkyl-
substituted c-DIMs demonstrate good anti-cancer properties towards the 
glioblastoma cell line, with compound 19 being superior. Thus, the compounds in 
series two were designed with the intention of improving the anti-cancer activity 
that was observed in series one.    
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3.2.4 – Series two cell viability results and discussion 
3.2.4.1 – Series two cell viability results 
Table 4 – IC50 values for compounds 20, 66, 67 and 38 against the U-87 MG 
cell line for 48 hours. 
The synthesis of compound 20 was firstly based on, as previously mentioned, a 
deactivating para-nitro group on the phenyl ring (compound 64) displayed slightly 
improved activity in comparison to compound 17, with a para-methoxy group (38 
µM [-NO2] vs 52 µM [-MeO]). Furthermore, formerly discussed literature states 
that halogenated phenyl substituted c-DIMs have an anti-proliferative effect 
towards colon cancer cells and oral squamous cell carcinoma.[107][108] Therefore, 
it was of interest to investigate the effects of a para-halogenated phenyl c-DIM 
against glioblastoma cells.  
Compound Chemical Structure IC50 (µM) 
20 
 
 
>250 
(91% cell viability at 
250 µM) 
66 
 
200 
67 
 
209 
38 
 
186 
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Previous research carried out within the Snape research group, has identified 
that 2-substituted indoles 69, 70 and 71, as seen in Figure 22, display moderately 
good anti-glioblastoma activity.[157][158][159] 
 
Figure 22 – 2-Arylindoles previously tested against the U87MG glioma cell line 
within the Snape research group.[157][158][159] 
Furthermore, previously discussed literature in section 1.4, states the anti-cancer 
activity of 2,2’-dimethyl and 2,2’-diphenyl DIM compounds towards breast cancer 
cell lines.[100][101] Lei et al also reported a 40-60% reduction in cell viability of colon 
cancer cell lines after treatment with 2,2’-dimethyl DIM-c-pPhF.[107] These 
findings suggest that adding methyl and phenyl substitution at position-2 of the 
indole rings, could potentially increase the anti-glioblastoma effects of c-DIMs.  
Therefore, taking the structure of the compound that displayed the best activity 
from series one, which was compound 19, and incorporating methyl and phenyl 
functionalisation at position-2 of the indole rings, provided the basis for the design 
of the 2,2’-substituted compounds 66 and 67.   
Studies regarding the anti-cancer activity of N,N’-methylated c-DIM compounds,  
state that N,N’-methylated DIM-c-pPhBr and DIM-c-pPhF compounds were 
totally inactive against colon cancer cells.[107] However, N,N’-dimethyl DIM has 
been reported to reduce cell proliferation in breast cancer cell lines.[101] Therefore, 
compound 38, which was the N,N’-methylated derivative of compound 19, was 
synthesised in order to analyse whether free NH groups were required for activity.  
 
 
69 70
71
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3.2.4.2 – Series two cell viability discussion 
As shown in Table 4, surprisingly, compound 20 exhibited a drastic reduction in 
anti-cancer activity in comparison to the c-DIM compounds in series 1. An IC50 
value could not be established for this compound, therefore the cell viability at 
250 µM is stated (91%). It would be expected that such a compound would 
demonstrate similar activity to compound 64 (IC50 38 µM), as they both contain 
an electron withdrawing substituent on the aromatic ring. However, only a slight 
positive effect was observed, with a 9% reduction in cell viability. Therefore, 
further research investigating the anti-glioblastoma effects of halogenated ring 
substituents should be carried out.  
Comparing compounds 66 and 67 with compound 19, shows that the addition of 
methyl and phenyl groups at position-2 of the indole rings dramatically reduced 
the activity of the compound. IC50 values of 200 µM and 209 µM for compounds 
66 and 67, respectively, demonstrate that the absence of substitution at position-
2 of the indole rings is required for anti-glioblastoma activity of symmetrical c-
DIMs.   
Compound 38 displays poor activity in comparison to compound 19 (32 µM vs 
186 µM, respectively), despite the only difference structurally being methylation 
at the N,N’-positions. Similar results have been found in related research whereby 
methylated c-DIM compounds were inactive against colon cancer cells.[107] These 
findings suggest that free NH groups are required for the anti-tumorigenic effect 
to glioblastoma cells. 
3.2.5 - Discussion of results from within the Snape research group 
Figure 23 shows 2-substituted indole compounds (69-71) and DIM derivates (72-
75) that have been tested against the U-87 MG glioblastoma cell line within the 
Snape research group. Compounds 69-71 each displayed good anti-glioblastoma 
effect towards U-87 MG cells.[157][158][159] However, the 2,2’-disubstituted DIM 
compounds 72-74 demonstrated poor activity, these findings are concordant with 
the results obtained in series 2 for the 2,2’-dimethyl and -diphenyl substituted c-
DIMs, compounds 66 and 67. 
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Figure 23  - Compounds tested against glioblastoma U-87 MG cell lines within 
the Snape research group. 2-Arylindoles 69-71, DIM derivatives 72–74 and their 
IC50 values.[157][158][159] 
Therefore, the question arises, why do the c-DIM compounds featured in series 
one and 2-substituted indole compounds (69-71) display good anti-glioblastoma 
effects, whereas 2,2’-substititued DIM’s and c-DIMs do not? For example, why is 
2-phenylindole (69) active against glioblastoma cells, yet its dimeric product (73) 
and corresponding c-DIM (67) are both essentially inactive? A potential reason 
for this difference in activity could be that, the groups at position-2 force the 
molecule to conform to a different shape than the DIM/c-DIMs with no 2,2’-
substitution. This possible difference in conformation, is indicative that the anti-
cancer mechanism of DIM and c-DIMs is through binding to a three dimensional 
biological target, which requires a specific structural arrangement of the 
molecule.  
Comparing compound 38, the N,N’-methylated derivative of compound 19 (186.2 
µM) with compound 75, N,N’-methylated DIM (>250 µM, cell viability 92%), shows 
that methylation of the N-positions causes a  significant reduction in activity. 
72, >250µM
73, 240µM
74, 240µM
75, >250µM
69 70 71
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These results are in accordance with each other, and previously mentioned 
literature.[107] Again, this is suggestive that a free NH group is necessary for anti-
glioblastoma activity, possibly due to the anti-cancer mechanism involving 
hydrogen bonding to a biological target via the amine groups of the indole 
motifs.[160][161] 
3.2.6 - Discussion of results in comparison to temozolomide 
As previously discussed in section 1.3.2, temozolomide is currently the main 
chemotherapeutic agent used in the treatment of high grade gliomas. As shown 
in the Graph below, in comparison to temozolomide, all the c-DIM analogues 
tested in this project show more potent inhibition of U-87 MG cell proliferation 
than temozolomide when treated for 48 hours, except from compound 20 as only 
91% cell viability was observed, thus, a reliable IC50 value was not obtainable. 
Therefore, Graph 2 does not include compound 20, Although each compound 
tested, including I3C and DIM, show improved anti-glioblastoma activity than 
temozolomide, compounds 19, 17, 64 and 65 especially demonstrate the most 
effective anti-proliferative effects against the malignant U-87 MG glioblastoma 
cell line, with compound 19 being superior overall. However, it is worth 
mentioning that temozolomide is an attractive chemotherapy drug due to its 100% 
oral bioavailability, whereby 100% of the drug enters the bloodstream when 
administered orally. Also, it has the ability to pass the blood brain barrier. The 
IC50 value of temozolomide after 48 hours treatment against U-87 MG 
glioblastoma cells slightly varies across literature, therefore an average IC50 value 
of 586 µM was calculated and used for comparison purposes and for Graph 
2.[162][163][164][165]  
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Graph 2 – Graph showing IC50 values of I3C, DIM and compounds tested 
(excluding compound 20), in comparison to temozolomide.[162][163][164][165] 
 
3.2.7. – Challenges encountered during cytotoxicity testing 
3.2.7.1 – Solubility of compounds 
A common problem encountered within the cytotoxicity testing stage of this 
project, was the precipitation or oiling-out of the compounds synthesised at 
high concentrations, when coming into contact with media. Therefore, when 
making the 10,000 µM working solution (shown in dilution scheme, Figure, 20) 
each compound required thorough mixing and warming in a 37 oC water bath. 
Compound  17 especially, crystallised when coming into contact with media 
when making the 10,000 µM working solution, despite heating in the water 
bath and thorough mixing using a vortex. Thus, making it not possible to make 
the 250 µM, 100 µM, 10 µM and 1 µM concentrations required for the cell 
viability assays. The solution to this problem was to avoid making a 10,000 
µM working solution, as this step involved the mixing of 250 µL of compound 
17 and 250 µL media – and it was this step that was causing the precipitation 
of compound 17. Figure 24 shows the serial dilution used for compound 17 in 
comparison to the other compounds, precipitation did not occur when using 
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the second serial dilution, as only half of the volume of 20 mM compound 17 
was being diluted with media than it was in serial dilution one.  
 
Figure 24 – Top row: the usual serial dilution followed to create the 250 µM 
concertation. Bottom row: the serial dilution followed to create the 250 µM 
concentration for compound 17 as this avoided the compound precipitating out 
in media. 
After adding the compounds to the 96 well plates, the plates were studied under 
microscope often throughout the treatment stage. Crystallisation or oiling-out of 
compounds was easily identifiable amongst cells under the microscope, as 
crystals were larger, darker and visible as clusters under the microscope. Figure 
25 shows U-87 MG cells on the left in comparison to compound 17 oiling out in 
media under the microscope. 
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Figure 25 – Left: Low density U-87 MG cells as seen under the microscope 
(magnification x100). Right: Compound 17 oiling-out in media (magnification 
x100). 
The precipitation of compound 17 at high concentrations, is also potentially visible 
in the cell viability graph shown below in Graph 3. The graph shows cell viability 
increasing at around 250 µM, this could possibly be a result of the compound 
crystallising over time at higher concentrations, and therefore having no effect on 
the cells.    
 
Graph 3 - U-87 MG % cell viability graph of U-87 MG cells after treatment with 
compound 17 after 48 hours. 
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3.2.7.2 – Contamination of cells  
Another recurring challenge in cytotoxicity testing was cell culture contamination, 
contaminants include bacteria, fungi, yeast, viruses and chemical contaminants. 
Bacterial and fungal contamination were the most common types of 
contamination encountered, however, they are also the easiest types to identify. 
Not only were bacterial and fungal contaminants easy to spot under the 
microscope, due to their difference in appearance to U-87 MG cells – 
bacteria/fungi are usually much darker and different structurally under the 
microscope. Culture medium contains a non-toxic pH indicator, called phenol red. 
As bacterial and fungal contamination results in the media becoming more acidic, 
a colour change from red (7.5 pH) to yellow (6.4 pH) is observed (Scheme 29). 
This obvious colour change made bacterial/fungal contaminated cultures easy to 
identify. Contaminated cultures were incinerated as soon as possible, new 
cryopreserved cells were then obtained from the liquid nitrogen freezer, defrosted 
and incubated in order to prepare for seeding.   
Red, pH 7.5
Yellow, 6.4
Scheme 29 – Chemical structure of phenol red and its colour change reaction. 
Cell culture contamination can arise from a number of different sources including; 
• Contact with non-sterile media, solutions or equipment 
• Airborne particles entering culture during passaging, seeding, treatment, 
transportation or incubating 
• Over-crowding of cultures within the incubators 
• Biological contaminants can grow or swim into culture vessels from outside 
of the vessels 
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As such a range of pathways can cause contamination, it was difficult to control, 
especially in a busy lab. The best way to reduce contamination problems was 
firstly, to practice good aseptic techniques; spray flasks and plates with 70% 
industrial methylated spirits (IMS) before placing cell cultures into fume hoods or 
incubators, to clean the fumehood before and after use, and clean the incubator 
on a regular basis using 70% Industrial methylated spirits (IMS) and Virkon. 
Virkon is a potent disinfectant that is effective in killing viruses, bacteria and fungi.  
Antibiotics are frequently used in cell cultures as a way to prevent bacterial 
contamination. For example, Penicillin-Streptomycin (Pen-Strep) – a mixture of 
penicillin and streptomycin is often used within cell cultures to minimise bacterial 
contamination. However, they should only be used as a last resort or for a very 
short time period. This is because continuous use of antibiotics can encourage 
the progression of antibiotic resistant strains. Antibiotics in cell cultures can also 
mask low-level contamination, which can advance and spread into wide-scale 
contamination when the antibiotic is removed from the media. Therefore, the use 
of antibiotics was not an appropriate measure to control contamination during cell 
cytotoxicity testing.  
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CHAPTER FOUR – CONCLUSION 
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4.1 – Conclusion 
Glioblastoma is the most aggressive and common malignant brain tumour in 
adults, with primary glioblastoma accounting for 90% of cases.[1] Glioblastoma is 
associated with extremely poor prognosis, long term survival is uncommon, as 
only 25% of patients survive two years.[1][2] Currently, the gold standard of care 
for the treatment glioblastoma is surgery, radiotherapy and the administration of 
the chemotherapeutic agent temozolomide. Although temozolomide extends the 
overall survival of patients, temozolomide resistance is a growing issue.[70] Thus, 
the development of new, much more effective pharmaceutical agents are 
necessary for the treatment of glioblastoma. 
Derived from cruciferous vegetables, the dimeric product of indole-3-carbinol 
(I3C) - 3,3’-diindolylmethane (DIM), has received considerable attention 
regarding its antitumorigenic activity towards various cancer cell lines.[7][90][[91][92] 
In addition to the basic structure of DIM, in vitro studies have also established 
anti-cancer effects of DIMs methylene bridge-substituted derivatives (c-DIMs), 
and its 2,2’-substituted derivatives.[10][100][101][103] However, the effects of c-DIMs 
against glioblastoma cells are seemingly currently unknown. 
This thesis successfully, for the first time, describes the anti-glioblastoma effects 
of c-substituted DIM derivatives. Using the MTS assay, cytotoxicity testing of I3C, 
DIM and the c-DIM compounds was carried out against the U-87 MG human 
glioblastoma cell line. From the in vitro studies, IC50 values for each compound 
were established, and structure activity relationships were identified. DIM 
displayed much better activity than I3C, (46 µM vs 158 µM, respectively), possibly 
due to the slow conversion of I3C into DIM at neutral pH. Compounds 19, 64 and 
65 displayed the most effective activity (IC50 values 31 µM, 38 µM and 33 µM, 
respectively), with compound 19 being superior overall. However, the N,N’- and 
2,2’- substituted c-DIM analogues displayed a reduction in activity, suggestive 
that free indole groups are essential for anti-glioblastoma activity.   
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4.2 – Future work 
Whilst this project demonstrates that c-DIMs display anti-glioblastoma effects, 
prospects remain to extend the scope of this research. Firstly, additional 
cytotoxicity testing of the best performing compounds 19, 64 and 65, should be 
carried out against alternative glioblastoma cell lines, as different genes are 
expressed within different cell lines. Therefore, comparisons can be made 
between cell viability results from other cell lines, popular alternative glioblastoma 
cell lines include U-118 MG and U-251 MG. 
In addition to glioblastoma cell lines, the c-DIM compounds ought to be tested on 
primary glioblastoma cultures – these are tumours obtained directly from 
glioblastoma patients. This would reflect more accurately how the compounds 
would act against actual glioblastoma tumour tissue, as opposed to a cell line, as 
cell lines do not entail the true diversity of a living tumour.  
Moreover, studies involving the testing of the compounds on healthy brain tissue 
should be carried out. This would establish the cytotoxicity of the compounds 
towards healthy brain cells. Ideally, anti-cancer agents should have the ability to 
distinguish between tumorigenic cells and normal, healthy cells. 
With regards to the structure of the compounds tested, it would be interesting to 
test the effects of unsymmetrical 2-substituted c-DIMs. For example, 
incorporating a methyl group at position-2 of one indole ring of compound 19. As 
the single-substituted c-DIM may not change in conformation to the extent we 
suspect the 2,2’-dimethyl c-DIM (66) did. Therefore, it would be of interest to 
compare the anti-glioblastoma activity of compound 19, with its 2-methyl 
substituted and 2,2’-dimethyl substituted derivatives. It would also be of interest 
to extend the exploration of the effects of functionalisation around the indole ring, 
for example, analysing whether substitution at positions 5 or 6 would increase or 
reduce the anti-cancer in comparison to the activity described in this thesis.  
Therefore, overall, this project has provided a good foundation for future 
investigation into the anti-cancer effects of c-DIM analogues towards 
glioblastoma. 
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CHAPTER FIVE – EXPERIMENTAL 
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5.1 - Materials 
Reactions were monitored using thin layer chromatography (TLC) using plastic-
backed TLC plates coated in silica G/UV254, run in various solvent systems and 
visualised using a UVP CHROMATO-VUE cabinet under short wave (254 nm) 
and long wave (365 nm) UV light, with p-anisaldehyde or potassium 
permanganate stain. Commercially available solvents and reagents were 
purchased from Sigma Aldrich, TCI, Fluorochem or ThermoFisher Scientific and 
were used with no further purification unless stated otherwise in the syntheses. 
Flash column chromatography was carried out on Davisil silica 60 Å (40-63 µm) 
chromatography grade silica, under bellows pressure. 
1H and C13 NMR spectra were recorded using a Bruker Fourier 300 (300 MHz) or 
Bruker Advance III 400 (400 MHz). δ indicates chemical shift in ppm and J 
indicates coupling constants in Hertz (Hz). Multiplicity of NMR signals are 
abbreviated using: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, 
sex = sextet, m = multiplet, dd = doublet of doublets, td = triplet of doublets. 
Assignments of NMR spectra was aided with the use of DEPT-135, and in some 
cases DEPT-90. LC-MS spectra were obtained using a Finnigan LCW Advantage 
Max, Finnigan PDA Plus detector. IR spectra were recorded using solid samples 
on a Thermo Nicolet IR-200 FT-IR. Melting points were obtained using Stuart 
digital melting point apparatus and are uncorrected.  
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Experimental 
5.2 - 3-[1H-Indol-3-yl(phenyl)methyl]-1H-indole (EJ-1-33-2) 
 
19 
To a stirred solution of indole (0.50 g, 4.2 mmol, 2 eq.) and benzaldehyde (0.226 
mL, 2.1 mmol, 1 eq.) in  deionised water (15 mL), was added concentrated 
sulfuric acid (0.232 mL, 4.2 mmol) and stirred at room temperature. The reaction 
was monitored by TLC using ethyl acetate: petroleum ether (30:70). Once the 
reaction reached completion according to TLC, the reaction mixture was 
extracted with ethyl acetate (30 mL) and washed with brine (2 x 30 mL). The 
organic layer was dried with magnesium sulfate, filtered via vacuum filtration and 
the remaining solution was evaporated to dryness in vacuo, leaving a red oil that 
was left to dry overnight in the fumehood. The crude product had traces of starting 
reagents, so therefore was purified by flash column chromatography (30:70 ethyl 
acetate: petroleum ether) to yield compound 19 as a red solid (0.598 g, 88% 
yield). 1H NMR (300 MHz, CDCl3) δH= 7.88 (2H, s, NH), 7.33-7.41 (m, 6H, Ar H), 
7.21-7.31 (m, 3H, Ar H), 7.18 (t, J = 7.5, 2H, Ar H), 6.99 (t, J = 7.5, 2H, Ar H), 
6.64 (s, 2H, Ar H), 5.89 (1H, s, CH). 13C NMR (75MHz, CDCl3): δc = 144.0 (Ar C), 
136.7 (Ar C), 128.8 (Ar CH), 128.2 (Ar CH), 127.0 (Ar C), 126.1 (Ar CH), 123. 7 
(Ar CH), 121. 9 (Ar CH), 120.0 (Ar CH), 119.7 (Ar C), 119.3 (Ar CH), 111.0 (Ar 
CH), 40.2 (CH). LC-MS (ESI) Calculated: 322.4, found: 321.56 (m/z).  IR (neat, 
cm-1) 3390 (N-H), 1335.50 (C-N). mp: 149-152 oC (ethyl acetate/ petroleum 
ether), literature mp: 142-144 oC.[166]  
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5.3 - 3-[1H-Indol-3-yl-(4-methoxyphenyl)methyl]-1H-indole (EJ 1-36-1) 
 
17 
Synthesised as compound 19 using 4-methoxybenzaldehyde (0.28 mL, 2.1 
mmol) to yield compound 17 as a brown solid (0.425 g, 57% yield). 
Chromatography solvent 20:80 ethyl acetate: petroleum ether. 1H NMR (300 
MHz, CDCl3): δH = 7.97 (s, 2H, NH), 7.39-7.45 (m, 4H, Ar H), 7.29-7.31 (m, 2H, 
Ar H), 7.22 (t, J = 7.5, 2H, Ar H), 7.06 (t, J = 7.0, 2H, Ar H), 6.87 (d, J = 8.0, 2H, 
Ar H), 6.70 (s, 2H, Ar H), 5.89 (s, 1H, CH), 3.84 (s, 3H, OCH3). 13C NMR (75 MHz, 
CDCl3): δc = 157.9 (Ar C), 136.7 (Ar C), 136.2 (Ar C), 129. 6 (Ar CH), 127.0 (Ar 
C), 125.5 (Ar CH), 123.5 (Ar CH), 121.9 (Ar CH), 120.0 (Ar CH), 120.0 (Ar C), 
113.5 (Ar CH), 111.0 (Ar CH), 55.22 (C-OCH3), 39.30 (CH). MS (ESI) calculated: 
352.43, found: 351.31 m/z. IR (neat, cm-1) 3392.96 (N-H), 1453.70 (C-H), 
1344.71 (C-N), 1256.17 (C-O-C). mp: 184-186 oC (ethyl acetate/ petroleum 
ether), literature mp: 186-187 oC.[166] 
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5.4 3-[1H-Indol-3-yl-(4-nitrophenyl)methyl]-1H-indole (EJ 1-39-2) 
 
64 
Synthesised as 19 using 4-nitrobenzaldehyde (0.3174 g, 2.1mmol) to yield 
compound 64 as a yellow solid (0.611 g, 73%). Chromatography solvent 30:70 
ethyl acetate: petroleum ether. 1H NMR (300 MHz, DMSO-d6): δH = 10.96 (s, 2H, 
NH), 8.15 (d, J = 8.0, 2H, Ar H), 7.61 (d, J = 8.0, 2H, Ar H), 7.36 (d, J = 8.0, 2H, 
Ar H), 7.29 (d, J = 8.0, 2H, Ar H), 7.05 (t, J = 7.5, 2H, Ar H), 6.86-6.90 (m, 4H, Ar 
H), 6.03 (s, 1H, CH). 13C NMR (75 MHz, DMSO-d6): δc = 153.60 (Ar C), 146.18 
(Ar C), 137.02 (Ar C), 129.91 (Ar CH), 126.79 (Ar C), 124.32 (Ar CH), 123.90 (Ar 
CH), 121.57 (Ar CH), 119.37 (Ar CH), 118.88 (Ar CH), 117.10 (Ar C), 112.05 (Ar 
CH), 39.9 (CH). MS (ESI) calculated: 367.4, found: 366.22 m/z. IR (neat cm-1) 
3448.48 (N-H), 1501.17 (N-O), 1340.51 (N-O), 1236.48 (C-N). mp: 221-223 oC 
(ethyl acetate/ petroleum ether), literature mp: 218-220 oC.[167] 
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5.5 - 3-[1-(1H-Indol-3-yl)-1-methyl-ethyl]-1H-indole (1-58-2) 
 
65 
 
Synthesised as 19 using an excess of acetone (2 mL) and was heated to 60 oC 
to yield 65 as white needles (0.214 g, 37%). Chromatography solvent 2:98 ethyl 
acetate: toluene. 1H NMR (300 MHz, CDCl3): δH = 7.92 (s, 2H, NH), 7.50 (d, J = 
8.0, 2H, Ar H), 7.38 (d, J = 8.0, 2H, Ar H), 7.15 (t, J = 7.5, 2H, Ar H), 7.11 (d, J = 
2.5, 2H, Ar H), 6.96 (t, J = 7.5, 2H, Ar H) 1.99 (s, 6H, CH3). 13C NMR (75 MHz, 
CDCl3): δc = 137.1 (Ar C), 126.3 (Ar C), 125.4 (Ar C), 121.4 (Ar CH), 121.3 (Ar  
CH), 120.5 (Ar CH), 118.7 (Ar CH), 111.1 (Ar CH), 34.9 (C), 30.0 (CH3). MS ESI 
calculated: 274.36 found: 273.14 m/z. IR (neat cm-1) 3393.8 (N-H), 1454.33 (C-
H), 1333.74 (C-N). Mp: 171-173 oC (ethyl acetate/ toluene), Literature mp: 168-
170 oC.[168] 
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5.6 - 3-[1H-Indol-3-yl-(4-fluorophenyl)methyl]-1H-indole (EJ 1-69-1) 
 
20 
Synthesised as 19 using 4-fluorobenzaldehyde (0.225 mL, 2.1 mmol) to yield 
compound 20 as a yellow solid (0.516 g, 72%). 1H NMR (300 MHz DMSO-d6): δH 
= 7.78 (s, 2H, NH), 7.33-7.37 (m, 4H, Ar H), 7.18 (d, J =  8.0, 2H, Ar H), 7.12 (t, 
J = 7.5, 2H, Ar H), 6.95-7.05 (m, 6H, Ar H), 5.67 (s, 1H, CH). 13C NMR (75 MHz, 
DMSO-d6): δc = 140.6 (Ar C), 137.5 (Ar C), 136.9 (Ar C), 130.7 (Ar CH), 125.9 (Ar 
C), 121.1 (Ar CH), 118.9 (Ar CH), 118.7 (Ar CH), 115.6 (Ar CH), 115.3 (Ar CH), 
111.6 (Ar CH), 110.2 (Ar C), 38.9 (CH). MS ESI calculated: 340.39, found: 340.07 
m/z. IR (neat cm-1) 3462.47 (N-H), 1321.14 (C-N), 1211.72 (C-F). mp: 103-106 
oC (ethyl acetate/ petroleum ether), literature mp: 100-102 oC.[168] 
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5.7 - 2-Methyl-3-[(2-methyl-1H-indol-3-yl)-phenyl-methyl]-1H-indole  
(EJ 1-63-2) 
 
 
66 
 
To a stirred solution of 2-methylindole (0.55 g, 4.2 mmol) and benzaldehyde 
(0.226 mL, 2.1 mmol) in DCM (15 mL), concentrated sulfuric acid (0.232 mL, 4.2 
mmol) was added. The reaction was left stirring for 24 hours. The desired product 
precipitated out in reaction mixture, it was filtered by vacuum filtration and washed 
with 20:80 ethyl acetate: DCM to yield compound 66 as a pink solid. (0.478 g, 
65%). 1H NMR (300 MHz, DMSO-d6): δH = 10.79 (s, 2H, NH), 7.16-7.28 (m, 7H, 
Ar H), 6.88 (t, J = 7.5, 2H, Ar H), 6.79 (d, J = 8.0, 2H, Ar H), 6.66 (t, J = 7.5, 2H, 
Ar H), 5.92 (s, 1H, CH), 2.06 (s, 6H, CH3). 13C NMR (75 MHz, DMSO-d6): δc = 
144.6 (Ar C), 135.4 (Ar C), 132.4 (Ar C), 129.1 (Ar CH), 128.6 (Ar C), 128.3 (Ar 
CH), 126.2 (Ar CH), 119.9 (Ar CH), 118.9 (Ar CH), 118.3 (Ar CH), 112.6 (Ar C), 
110.7 (Ar CH), 38.9 (CH), 12.3 (CH3). MS ESI calculated: 350.46, found: 349.36 
m/z. IR (neat cm-1) 3392.84 (N-H), 1458.87 (C-H), 1336.85 (C-N). mp: 247-249 
oC (ethyl acetate/DCM), literature mp: 246-247 oC.[166] 
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5.8 - 2-Phenyl-3-[phenyl-(2-phenyl-1H-indol-3-yl)methyl]-1H-indole 
 (EJ 1-64-1) 
 
67 
Synthesised as compound 66 using 2-phenylindole (0.8116 g, 4.2 mmol) and 
benzaldehyde (0.226 mL, 2.1 mmol) to yield compound 67 as a grey solid (0.529 
g, 53%). 1H NMR (300 MHz, DMSO-d6): δH = 11.38 (s, 2H, NH), 7.37 (d, J = 8.0, 
2H, Ar H), 7.28-7.30 (m, 5H, Ar H), 7.20-7.25 (m, 8H, Ar H), 7.14 (d, J = 7.0, 2H, 
Ar H), 7.01 (t, J = 7.5, 2H, Ar H), 6.89 (d, J = 8.0, 2H, Ar H), 6.67 (t, J = 7.5, 2H, 
Ar H)  5.96 (s, 1H, CH). 13C NMR (75 MHz, DMSO- d6): δc= 145.9 (Ar C), 136.7 
(Ar C), 135.7 (Ar C), 133.2 (Ar C), 129.9 (Ar C), 129.1 (Ar CH), 128.8 (Ar CH), 
128.6 (Ar CH), 128.5 (Ar CH), 127.7 (Ar CH), 126.5 (Ar CH), 121.4 (Ar CH), 121.2 
(Ar CH), 119.0 (Ar CH), 114.6 (Ar C), 111.8 (Ar CH), 40.3 (CH). MS ESI 
calculated: 474.59 found: 473.53 m/z. IR (neat cm-1) 3419.99 (N-H), 1307.26 (C-
N). mp: 263-265 oC (ethyl acetate/DCM), literature mp: 266-268 oC.[169] 
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5.9 - 1-Methyl-3-[(1-methylindol-3-yl)-phenyl-methyl]indole (EJ 1-75-2) 
 
38 
THF (20 mL) was dried using 1 Å molecular sieves stirring for 25 minutes. 
Subsequently, compound 19 (0.322 g, 10 mmol) was added, NaH 60% mineral 
oil (0.12 g, 30 mmol) was then added and the solution was stirred at room 
temperature for 20 minutes. Next, MeI (0.426 g, 30 mmol) was added, and the 
reaction was allowed to stir for 2 hours. Once reaction had reached completion 
the reaction mixture was extracted with 1 M aqueous HCl (30 mL) and brine (30 
mL). The organic layer was dried with magnesium sulfate and the remaining 
solution was evaporated to dryness in vacuo. The crude product was purified by 
flash column chromatography (30:70) ethyl acetate: petroleum ether) to yield 
compound 38 as a red solid (0.279 g, 80%) 1H NMR (300 MHz CDCl3): δH = 7.30-
7.41 (m, 8H, Ar H), 7.19-7.24 (m, 3H, Ar H), 7.02 (t, J = 7.5, 2H, Ar H), 6.53 (s, 
2H, Ar H), 5.88 (s, 1H, CH), 3.70 (s, 6H, CH3). 13C NMR (75 MHz, CDCl3): δc = 
144.4 (Ar C), 137.3 (Ar C), 128.6 (Ar CH), 128.2 (Ar CH), 128.2 (Ar CH), 127.4 
(Ar  C), 126.0 (Ar CH), 121.4 (Ar CH), 120.0 (Ar CH), 118.6 (Ar CH), 118.2 (Ar 
C), 109.0 (Ar CH), 40.0 (CH), 32.7 (CH3). MS ESI calculated: 350.46, found: 
349.27 m/z. IR (neat cm-1) 2850.74 (N-CH3), 1445.54 (C-H), 1326.55 (C-N). 
Mp:193 -196 oC (ethyl acetate/ petroleum ether), literature melting point: 181-183 
oC.[170] 
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Cell viability graphs 
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Compound 19 
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Compound 64 
 
Compound 65 
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Compound 20 
 
Compound 66 
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Compound 67 
 
Compound 38 
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Analysis of selected compounds 
1H NMR of compound 64 
 
 
 
 
 
 
 
 
126 
 
 
1H NMR of compound 66 
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13C NMR of compound 19 
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DEPT-135 NMR of compound 65 
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DEPT-90 NMR of compound 64  
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LC-MS of compound 20 
 
 
LC-MS of compound 38 
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IR Spectra of compound 66 
 
 
IR spectra of compound 67 
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